COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM

Abstract
This disclosure relates to the use of RNA oligonucleotides, compositions and methods useful for reducing ALDH2 or other target gene expression, in the central nervous system. In some embodiments, the oligonucleotide is used in methods of treating neurological diseases. Stable oligonucleotide derivatives that have enhanced activity in the central nervous system are provided.
Description
FIELD OF THE INVENTION

The present application relates to the use of RNA interference oligonucleotides for the degradation of specific target mRNA's, particularly uses relating to the treatment of neurological conditions.


REFERENCE TO THE SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 400930-021WO_ST25.txt created on Apr. 3, 2020 and is 128 kilobytes in size. The information in electronic format of the Sequence Listing is incorporated herein by reference in its entirety.


BACKGROUND OF THE INVENTION

RNA interference (RNAi) is an innate cellular process that involves multiple RNA-protein interactions. Its gene silencing activity is activated when a double-stranded RNA (dsRNA) molecule of greater than 19 duplex nucleotides enters the cells, causing degradation of both the dsRNA and single stranded RNA (endogenous mRNA) of identical sequences.


More specifically, the RNA interference (RNAi) mechanism inhibits or activates gene expression at the stage of translation or by hindering the transcription of specific genes. RNAi targets include RNA from viruses and transposons, and RNAi inhibition of expression also plays a role in regulating development and genome maintenance. The RNAi pathway is initiated by the enzyme dicer, which cleaves long, double-stranded RNA (dsRNA) molecules into short fragments of 20-25 base pairs. One of the two strands of each fragment, known as the guide strand, is then incorporated into the RNA-induced silencing complex (RISC). The RISC is a multiprotein complex, specifically a ribonucleoprotein, which incorporates one strand of a single-stranded RNA the “antisense strand” or “guide strand” (ssRNA) fragment to guide RISC to a complementary mRNA for subsequent endonucleolytic cleavage. Once found, one of the proteins in RISC, called Argonaute, activates and cleaves the mRNA.


In general, difficulties in the use of RNAi technology in the past have included off-target effects related to the use of guide strands insufficiently tailored to affect specific genes, delivery to multiple organ systems where gene expression of the target gene may be desirable and having the capability to target oligonucleotides to organ systems other than the liver where the characteristics of hepatocytes assist in the uptake and effectiveness of RNAi technology.


In terms of pathologies of the Central Nervous System (“CNS”) most pharmacotherapies currently being used for treatment of neurodegenerative or inflammatory CNS disorders target molecules that are localized downstream in the pathogenic cascade. Therefore, their effects are often not specific and are moderate or simply ineffective with regard to disease modulation. Other approaches that may add to the medical arsenal are those that focus on different methods of modulating or controlling a disease. Among these innovative therapeutic strategies is the ‘silencing’ of genes that cause or directly contribute to disease phenotypes using RNAi technologies. The difficulties in using this therapeutic avenue have been identifying specific candidate genes, specific targeting to the CNS, durability of therapeutic effect and the exit from the CNS of RNAi modalities that could affect other tissues.


The aldehyde dehydrogenase-2 (ALDH2) gene encodes an important biologically active enzyme, ALDH2. ALDH2 participates in the metabolism and detoxification of aldehyde and metabolizes short-chain aliphatic aldehydes and converted acetaldehyde into acetate it is active in the human liver. ALDH2 has been shown involved in the metabolism of other biogenic aldehydes, such as 4-hydroxynonenal, 3,4-dihydroxyphenylacetaldehyde, and 3,4-dihydroxyphenylglycoaldehyde. Recent studies have indicated that ALDH2 is also expressed in the CNS where it exerts protective effects on the cardio-cerebral vascular system and central nervous system. Single nucleotide polymorphisms (SNPs) of the ALDH2 gene have been reported to be associated with the risks for several neurological diseases, such as neurodegenerative diseases, cognitive disorders, and anxiety disorders. Removing or inhibiting the ALDH2 gene in the CNS prevents or limits the biological activity of the active enzyme and is relatively easily measured.


BRIEF SUMMARY OF THE INVENTION

Aspects of the disclosure relate to oligonucleotides and related methods for treating a neurological disease in a subject. In some embodiments, potent RNAi oligonucleotides are provided for their selective activity in the CNS. In the present invention the oligonucleotides administered into the CNS are effective at delivering an ALDH2 targeting guide strand that loads into the RISC complex and that thereafter is effective in the inhibition of ALDH2 expression in the central nervous system of a subject via the cleavage of ALDH2 mRNAs. In some embodiments, RNAi oligonucleotides provided herein target key regions of ALDH2 mRNA (referred to as hotspots) that are particularly amenable to targeting using such oligonucleotide-based approaches (see Table 5). In some embodiments, RNAi oligonucleotides provided herein incorporate modified phosphates, nicked tetraloop structures, and/or other modifications that improve activity, bioavailability and/or minimize the extent of enzymatic degradation after in vivo administration to the central nervous system. The ALDH2 gene targeting sequence, according to the present invention, could be replaced with a guide strand directed to a gene sequence of interest in a fashion that would allow the specific degradation of mRNA in the CNS and thereby degrade or inhibit the production of a protein of interest. Where this protein is a contributor to gain of function pathology—the negative aspects of the pathology are reduced or eliminated while the RISC complex remains active in cleaving the target mRNA. Other oligonucleotides of the current invention can also be put into to the CNS to modulate or inhibit the expression of specific target genes in a therapeutically meaningful way.


Some aspects of the present disclosure provide methods of reducing expression of ALDH2 in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length, wherein the antisense strand has a region of complementarity to a target sequence of ALDH2 as set forth in any one of SEQ ID NOs: 601-607, wherein the region of complementarity is at least 12 contiguous nucleotides in length. In some embodiments, the region of complementarity is fully complementary to the target sequence of ALDH2. In some embodiments, the antisense strand is 19 to 27 nucleotides in length.


In some embodiments, the oligonucleotide further comprises a sense strand of 15 to 40 nucleotides in length, wherein the sense strand forms a duplex region with the antisense strand. In some embodiments, the sense strand is 19 to 40 nucleotides in length.


In some embodiments, the duplex region is at least 12 nucleotides in length. In some embodiments, the region of complementarity to ALDH2 is at least 13 contiguous nucleotides in length.


In some embodiments, the antisense strand comprises a sequence as set forth in any one of SEQ ID NOs: 591-600. In some embodiments, the sense strand comprises a sequence as set forth in any one of SEQ ID NOs: 581-590, 608, and 609. In some embodiments, the sense strand consists of a sequence as set forth in any one of SEQ ID NOs: 591-600. In some embodiments, the antisense strand consists of a sequence as set forth in any one of SEQ ID NOs: 581-590, 608, and 609.


In some embodiments, the oligonucleotide comprises at least one modified nucleotide. In some embodiments, the modified nucleotide comprises a 2′-modification. In some embodiments, the 2′-modification is a modification selected from: 2′-aminoethyl, 2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl, 2′-aminodiethoxymethanol, 2′-adem, and 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid. In some embodiments, all of the nucleotides of the oligonucleotide are modified.


In some embodiments, the oligonucleotide comprises at least one modified internucleotide linkage. In some embodiments, the at least one modified internucleotide linkage is a phosphorothioate linkage.


In some embodiments, the oligonucleotide comprises a phosphorothioate linkage between one or more of: positions 1 and 2 of the sense strand, positions 1 and 2 of the antisense strand, positions 2 and 3 of the antisense strand, positions 3 and 4 of the antisense strand, positions 20 and 21 of the antisense strand, and/or positions 21 and 22 of the antisense strand. In some embodiments, the oligonucleotide has a phosphorothioate linkage between each of: positions 1 and 2 of the sense strand, positions 1 and 2 of the antisense strand, positions 2 and 3 of the antisense strand, positions 20 and 21 of the antisense strand, and positions 21 and 22 of the antisense strand.


In some embodiments, the 4′-carbon of the sugar of the 5′-nucleotide of the antisense strand comprises a phosphate analog. In some embodiments, the phosphate analog is oxymethylphosphonate, vinylphosphonate, or malonylphosphonate.


In some embodiments, a uridine present at the first position of an antisense strand comprises a phosphate analog. In some embodiments, the oligonucleotide comprises the following structure at position 1 of the antisense strand:




embedded image


In some embodiments, the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length. In some embodiments, L is a tetraloop. In some embodiments, L is 4 nucleotides in length. In some embodiments, L comprises a sequence set forth as GAAA.


In some embodiments, one or more of the nucleotides of the GAAA sequence at positions 27-30 on the sense strand is conjugated to a monovalent GalNAc moiety. In some embodiments, each of the nucleotides of the GAAA sequence at positions 27-30 on the sense strand is conjugated to a monovalent GalNAc moiety. In some embodiments, each of A of the GAAA sequence (at positions 28-30) on the sense strand is conjugated to a monovalent GalNAc moiety. In some embodiments, an oligonucleotide herein comprises a monovalent GalNAc attached to a Guanidine nucleotide, referred to as [ademG-GalNAc] or 2′-aminodiethoxymethanol-Guanidine-GalNAc, as depicted below:




embedded image


In some embodiments, an oligonucleotide herein comprises a monovalent GalNAc attached to an adenine nucleotide, referred to as [ademA-GalNAc] or 2′-aminodiethoxymethanol-Adenine-GalNAc, as depicted below.




embedded image


In some embodiments, the GAAA motif at positions 27-30 on the sense strand comprises the structure:




embedded image


wherein:


L represents a bond, click chemistry handle, or a linker of 1 to 20, inclusive, consecutive, covalently bonded atoms in length, selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, and combinations thereof; and X is O, S, or N.


In some embodiments, L is an acetal linker. In some embodiments, X is O.


In some embodiments, the GAAA sequence at positions 27-30 on the sense strand comprises the structure:




embedded image


In some embodiments, each of the A in the GAAA sequence is conjugated to a GalNAc moiety (e.g., at positions 28-30 on the sense strand). In some embodiments, the GalNAc moiety conjugated to each of A has the structure illustrated above, except that G is unmodified or has a 2′ modification on the sugar moiety. In some embodiments, the G in the GAAA sequence comprises a 2′-O-methyl modification (e.g., 2′-O-methyl or 2′-O-methoxyethyl), and each of A in the GAAA sequence is conjugated to a GalNAc moiety, such as in portions of the structures illustrated above.


In some embodiments, the G in the GAAA sequence comprises a 2′-OH. In some embodiments, each of the nucleotides in the GAAA sequence comprises a 2′-O-methyl modification. In some embodiments, each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification. In some embodiments, each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification. In some embodiments, each of the A in the GAAA sequence comprises a 2′-adem modification and the G in the GAAA sequence comprises a 2′-O-methyl modification.


In some embodiments, the antisense strand and the sense strand are not covalently linked.


In some embodiments, the oligonucleotide is administered intrathecally, intraventricularly, intracavitary, or interstitially. In some embodiments, the oligonucleotide is administered via injection or infusion.


In some embodiments, the subject has a neurological disorder. In some embodiments, the neurological disorder is selected from: neurodegenerative diseases, cognitive disorders, and anxiety disorders.


In some embodiments, the method of reducing expression of ALDH2 in a subject comprises administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand and a sense strand,


wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to ALDH2,


wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length,


and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.


In some embodiments, the method of reducing expression of ALDH2 in a subject comprises administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand and a sense strand that are not covalently linked,


wherein the antisense strand comprises a sequence as set forth in SEQ ID NO: 595 and the sense strand comprises a sequence as set forth in SEQ ID NO: 585,


wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L is a tetraloop comprising a sequence set forth as GAAA, and wherein the GAAA sequence comprises a structure selected from the group consisting of:


(i) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-O-methyl modification;


(ii) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-OH;


(iii) each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification;


(iv) each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification;


(v) each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification; and


(vi) each of the A in the GAAA sequence comprises a 2′-aminodiethoxymethanol modification and the G in the GAAA sequence comprises a 2′-O-methyl modification.


In some embodiments, the method of reducing expression of ALDH2 in a subject comprises administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand and a sense strand that are not covalently linked, wherein the antisense strand comprises a sequence as set forth in SEQ ID NO: 595 and the sense strand comprises a sequence as set forth in SEQ ID NO: 609.


In some embodiments, the oligonucleotide reduces expression detectable in somatosensory cortex, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, and/or spinal cord.


Other aspects of the present disclosure provide methods of reducing expression of a gene of interest in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length, wherein the antisense strand has a region of complementarity to a target sequence of said gene of interest that expresses in the CNS, wherein the region of complementarity is at least 12 contiguous nucleotides in length.


In some embodiments, the gene of interest is selected from the group consisting of ALDH2, Ataxin-1, Ataxin-3, APP, BACE1, DYT1, and SOD1.


In some embodiments, the oligonucleotide reduces expression detectable in somatosensory cortex, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, and/or spinal cord.


In some embodiments, the oligonucleotide further comprising elements that are degraded by nucleases outside the CNS such that said nucleotide is no longer capable of reducing expression of a gene of interest in a subject in tissues outside the CNS.


In some embodiments, the oligonucleotide further comprises modifications such that it cannot easily exit the CNS.


Other aspects of the present disclosure provide methods of treating a neurological disorder, the method comprising administering to the cerebrospinal fluid of a subject in need thereof an oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length, wherein the antisense strand has a region of complementarity to a target sequence of ALDH2 as set forth in any one of SEQ ID NOs: 601-607, wherein the region of complementarity is at least 12 contiguous nucleotides in length.


In some embodiments, the method comprises administering to the cerebrospinal fluid of a subject in need thereof an oligonucleotide comprising an antisense strand and a sense strand,


wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to ALDH2,


wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length,


and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.


In some embodiments, the neurological disorder is a neurodegenerative disease. In some embodiments, the neurological disorder is an anxiety disorder.


In some embodiments, the oligonucleotide is administered intrathecally, intraventricularly, intracavitary, or interstitially. In some embodiments, the oligonucleotide is administered via injection or infusion.


In some embodiments, the oligonucleotide reduces expression detectable in somatosensory cortex, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, and/or spinal cord.


Other aspects of the present disclosure provide oligonucleotides comprising an antisense strand and a sense strand,


wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to ALDH2,


wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L is a tetraloop and comprises a sequence set forth as GAAA, wherein the GAAA sequence comprises a structure selected from the group consisting of:


(i) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-O-methyl modification;


(ii) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-OH;


(iii) each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification;


(iv) each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification;


(v) each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification; and


(vi) each of the A in the GAAA sequence comprises a 2′-adem modification and the G in the GAAA sequence comprises a 2′-O-methyl modification,


and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.


In some embodiments, the antisense strand comprises a sequence set forth in any one of SEQ ID NOs: 591-600. In some embodiments, the sense strand comprises a sequence set forth in any one of SEQ ID NOs: 581-590. Compositions comprising these oligonucleotides and an excipient are provided. In some embodiments, a method of reducing expression ALDH2 in a subject comprises administering the composition to the cerebrospinal fluid of the subject. In some embodiments, a method of treating a neurological disease in a subject in need thereof comprises administering the composition to the cerebrospinal fluid of the subject.


Other aspects of the present disclosure provide methods of reducing expression of a target gene in a subject, the method comprising administering an oligonucleotide to the cerebrospinal fluid of the subject, wherein the oligonucleotide comprises an antisense strand and a sense strand,


wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to the target gene,


wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length,


and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.


In some embodiments, Lis a tetraloop. In some embodiments, L is 4 nucleotides in length. In some embodiments, L comprises a sequence set forth as GAAA. In some embodiments, each of the A in GAAA sequence is conjugated to a GalNAc moiety. In some embodiments, the G in the GAAA sequence comprises a 2′-O-methyl modification. In some embodiments, the G in the GAAA sequence comprises a 2′-OH. In some embodiments, each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification. In some embodiments, each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification. In some embodiments, each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification. In some embodiments, each of the A in the GAAA sequence comprises a 2′-adem and the G in the GAAA sequence comprises a 2′-O-methyl modification.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate certain embodiments, and together with the written description, serve to provide non-limiting examples of certain aspects of the compositions and methods disclosed herein.



FIG. 1 shows the regions of the brain for intraventricular (ICV) administration of RNAi oligonucleotides of interest to a CD-1 mouse (25 g female).



FIG. 2 shows the distribution of Fast Green dye throughout the ventricular system after direct injection of the dye into the right lateral ventricle. 10 μL of FastGreen dye (2.5% in sterile PBS) was delivered at 1 μL/s via 33G Neuros syringe to the right lateral ventricle of a female CD-1 mouse.



FIGS. 3A-3F show the brain injection site for the GalNAc conjugated ALDH2 oligonucleotides (FIG. 3A), and the activity of the oligonucleotides in reducing ALDH2 expression in the liver (FIG. 3B), the hippocampus (FIG. 3C), the somatosensory cortex (FIG. 3D), the striatum (FIG. 3E) and the cerebellum (FIG. 3F). The GalNAc conjugated ALDH2 oligonucleotides were administered via intraventricular administration (100 μg dose, equivalent to 4 mg/kg).



FIG. 4 shows that one single 100 μg dose of GalNAc-conjugated ALDH2 oligonucleotides administered to mice via ICV administration showed similar activities in reducing ALDH2 expression in the cerebellum, compared to a benchmark 900 μg dose (in rat) via intra administration for a different RNAi oligonucleotide (conjugated or unconjugated).



FIG. 5 shows the potency of GalNAc conjugated -ALDH2 oligonucleotides in reducing ALDH2 expression in different brain regions after ICV administration. The remaining ALDH2 mRNA levels were assessed in different brain regions after 5 days (for 100 μg dose) or after 7 days (for 250 μg or 500 μg doses).



FIG. 6 shows the dose response (250 μg or 500 μg) and time course (28 days post administration) of the activities of GalNAc-conjugated ALDH2 oligonucleotides in reducing ALDH2 mRNA expression in various brain regions. The data indicates sustained silencing throughout the brain following a single, ICV injection of the GalNAc-conjugated ALDH2 oligonucleotides.



FIG. 7 shows the dose response (250 μg or 500 μg) and time course (28 days post administration) of the activities of GalNAc-conjugated ALDH2 oligonucleotides in reducing ALDH2 mRNA expression throughout the spinal cord. The data indicates sustained silencing throughout the brain following a single, ICV injection of the GalNAc-conjugated ALDH2 oligonucleotides.



FIG. 8 shows the dose response (100 μg, 250 μg, or 500 μg) and time course (7 days post administration for 100 μg dose, 28 days post administration for 250 μg or 500 μg doses) of the activities of GalNAc-conjugated ALDH2 oligonucleotides in reducing ALDH2 mRNA expression in the liver. The data indicates sustained silencing in the liver following a single administration of the GalNAc-conjugated ALDH2 oligonucleotides.



FIG. 9 shows two-month (56 days) efficacy of GalNAc-conjugated ALDH2 oligonucleotides throughout distinct brain regions after a single, bolus ICV injection (250 μg or 500 μg).



FIG. 10 shows two-month (56 days) efficacy of GalNAc-conjugated ALDH2 oligonucleotides throughout the spinal cord after a single, bolus ICV injection (250 μg or 500 μg).



FIG. 11 show the results of a neurotoxicity study indicating that no glial fibrillary acidic protein (GFAP) upregulation is observed following administration of either 250 or 500 μg of the GalNAc conjugated ALDH2 oligonucleotides. The GalNAc conjugated ALDH2 oligonucleotides did not induce gliosis (a reactive change in glial cells in response to CNS injury).



FIG. 12 shows the activities of the ALDH2 RNAi oligonucleotide derivatives shown in FIG. 23 in reducing ALDH2 expression in the liver after a bolus ICV injection.



FIG. 13 shows activities of the ALDH2 RNAi oligonucleotide derivatives shown in FIG. 23 in reducing ALDH2 expression in various regions of the brain. The data indicates that GalNAc conjugation is not required for efficacy throughout the brain.



FIG. 14 shows the exposure to ALDH2 RNAi oligonucleotide derivatives and ALDH2 mRNA silencing in the frontal cortex following bolus ICV injection. The glia index (glial cell to neuronal cell ratio, also termed “GNR”) in frontal cortex is 1.25.



FIG. 15 shows the exposure to ALDH2 RNAi oligonucleotide derivatives and ALDH2 mRNA silencing in the striatum following bolus ICV injection. The glia index (glial cell to neuronal cell ratio, also termed “GNR”) in striatum varies.



FIG. 16 shows the exposure to ALDH2 RNAi oligonucleotide derivatives and ALDH2 mRNA silencing in the somatosensory cortex following bolus ICV injection. The glia index (glial cell to neuronal cell ratio, also termed “GNR”) in somatosensory cortex is 1.25.



FIG. 17 shows the exposure to ALDH2 RNAi oligonucleotide derivatives and ALDH2 mRNA silencing in the hippocampus following bolus ICV injection. The glia index (glial cell to neuronal cell ratio, also termed “GNR”) in hippocampus is 1.25.



FIG. 18 shows the exposure to ALDH2 RNAi oligonucleotide derivatives and ALDH2 mRNA silencing in hypothalamus following bolus ICV injection. The glia index (glial cell to neuronal cell ratio, also termed “GNR”) in hypothalamus is 1.25.



FIG. 19 shows the exposure to ALDH2 RNAi oligonucleotide derivatives and ALDH2 mRNA silencing in cerebellum following bolus ICV injection. The glia index (glial cell to neuronal cell ratio, also termed “GNR”) in cerebellum 0.25.



FIG. 20 shows a summary of relative exposure ALDH2 RNAi oligonucleotide derivatives across different brain regions.



FIG. 21 shows the exposure to ALDH2 RNAi oligonucleotide derivatives and ALDH2 mRNA silencing across the spinal cord following bolus ICV injection. The glia index (glial cell to neuronal cell ratio, also termed “GNR”) in spinal cord is about 5.



FIG. 22 shows the structures of the different linkers used in the tetraloop of the GalNAc-conjugated ALDH2 oligonucleotides.



FIG. 23 shows the exemplary structures of the oligonucleotide derivatives for use in the CNS. The oligonucleotides shown in the figure target ALDH2.





DETAILED DESCRIPTION OF THE INVENTION

In some aspects, the disclosure provides oligonucleotides targeting ALDH2 mRNA that are effective for reducing ALDH2 expression in cells, particularly the CNS. The carrier oligonucleotide structure of the invention and the insertion into the CNS will allow the treatment of neurological diseases. Accordingly, in related aspects, the disclosure provides methods of treating neurological diseases by selectively reducing gene expression in the central nervous system. In certain embodiments, ALDH2 targeting oligonucleotides derivatives provided herein are designed for delivery to the cerebrospinal fluid for reducing ALDH2 expression in the central nervous system.


In some embodiments, it is provided herein that, different oligonucleotide size, multimerization and/or molecular weight changes affect the ability of the oligonucleotide to leave CNS. The oligonucleotides will selectively function in the nuclease-lite CNS. Though the oligonucleotides can eventually enter the lymphatic system from the CNS, they will be degraded as they enter a nuclease-rich environment, thus preventing off target effects outside of the CNS. This effectively allows the engineering of a “kill switch” that will allow activity in the CNS and prevent off-target effects in other tissues.


Further aspects of the disclosure, including a description of defined terms, are provided below.


I. Definitions

ALDH2: As used herein, the term, “ALDH2” refers to the aldehyde dehydrogenase 2 family (mitochondrial) gene. ALDH2 encodes proteins that belong to the aldehyde dehydrogenase family of proteins and function as the second enzyme of the oxidative pathway of alcohol metabolism that synthesizes acetate (acetic acid) from ethanol. Homologs of ALDH2 are conserved across a range of species, including human, mouse, rat, non-human primate species, and others (see, e.g., NCBI HomoloGene:55480). ALDH2 also has homology to other aldehyde dehydrogenase encoding genes, including, for example, ALDH1A1. In humans, ALDH2 encodes at least two transcripts, namely NM_000690.3 (variant 1) and NM_001204889.1 (variant 2), each encoding a different isoform, NP_000681.2 (isoform 1) and NP_001191818.1 (isoform 2), respectively. Transcript variant 2 lacks an in-frame exon in the 5′ coding region, compared to transcript variant 1, and encodes a shorter isoform (2), compared to isoform 1. Polymorphisms in ALDH2 have been identified (see, e.g., Chang et al., “ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective,” J Biomed Sci., 2017, 24(1):19. Review).


Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).


Administering: As used herein, the terms “administering” or “administration” means to provide a substance (e.g., an oligonucleotide) to a subject in a manner that is pharmacologically useful (e.g., to treat a condition in the subject). In some embodiments, the oligonucleotides of the present disclosure are administered to the cerebrospinal fluid of a subject, e.g., via intraventricular, intracavitary, intrathecal, or interstitial injection or infusion. This is particularly true for neurodegenerative diseases like ALS, Huntington's Disease, Alzheimer's Disease or the like. The compounds can also be administered by transfection or infection using methods known in the art, including but not limited to the methods described in McCaffrey et al., Nature, 2002, 418(6893):38-9 (hydrodynamic transfection), or Xia et al., Nature Biotechnol., 2002, 20(10):1006-10 (viral-mediated delivery);


Cerebrospinal fluid: As used herein, the term “cerebrospinal fluid” refers to the fluid surrounding the brain and spinal cord. Cerebrospinal fluid generally occupies space between the arachnoid membrane and the pia mater. Additionally, cerebrospinal fluid is generally understood to be produced by ependymal cells in the choroid plexuses of the ventricles of the brain and absorbed in the arachnoid granulations.


Complementary: As used herein, the term “complementary” refers to a structural relationship between nucleotides (e.g., two nucleotide on opposing nucleic acids or on opposing regions of a single nucleic acid strand) that permits the nucleotides to form base pairs with one another. For example, a purine nucleotide of one nucleic acid that is complementary to a pyrimidine nucleotide of an opposing nucleic acid may base pair together by forming hydrogen bonds with one another. In some embodiments, complementary nucleotides can base pair in the Watson-Crick manner or in any other manner that allows for the formation of stable duplexes. In some embodiments, two nucleic acids may have nucleotide sequences that are complementary to each other so as to form regions of complementarity, as described herein.


Deoxyribonucleotide: As used herein, the term “deoxyribonucleotide” refers to a nucleotide having a hydrogen at the 2′ position of its pentose sugar as compared with a ribonucleotide. A modified deoxyribonucleotide is a deoxyribonucleotide having one or more modifications or substitutions of atoms other than at the 2′ position, including modifications or substitutions in or of the sugar, phosphate group or base.


Double-stranded oligonucleotide: As used herein, the term “double-stranded oligonucleotide” refers to an oligonucleotide that is substantially in a duplex form. In some embodiments, complementary base-pairing of duplex region(s) of a double-stranded oligonucleotide is formed between antiparallel sequences of nucleotides of covalently separate nucleic acid strands. In some embodiments, complementary base-pairing of duplex region(s) of a double-stranded oligonucleotide is formed between antiparallel sequences of nucleotides of nucleic acid strands that are covalently linked. In some embodiments, complementary base-pairing of duplex region(s) of a double-stranded oligonucleotide is formed from a single nucleic acid strand that is folded (e.g., via a hairpin) to provide complementary antiparallel sequences of nucleotides that base pair together. In some embodiments, a double-stranded oligonucleotide comprises two covalently separate nucleic acid strands that are fully duplexed with one another. However, in some embodiments, a double-stranded oligonucleotide comprises two covalently separate nucleic acid strands that are partially duplexed, e.g., having overhangs at one or both ends. In some embodiments, a double-stranded oligonucleotide comprises antiparallel sequences of nucleotides that are partially complementary, and thus, may have one or more mismatches, which may include internal mismatches or end mismatches.


Duplex: As used herein, the term “duplex,” in reference to nucleic acids (e.g., oligonucleotides), refers to a structure formed through complementary base-pairing of two antiparallel sequences of nucleotides.


Excipient: As used herein, the term “excipient” refers to a non-therapeutic agent that may be included in a composition, for example, to provide or contribute to a desired consistency or stabilizing effect.


Loop: As used herein, the term “loop” refers to an unpaired region of a nucleic acid (e.g., oligonucleotide) that is flanked by two antiparallel regions of the nucleic acid that are sufficiently complementary to one another, such that under appropriate hybridization conditions (e.g., in a phosphate buffer, in a cells), the two antiparallel regions, which flank the unpaired region, hybridize to form a duplex (referred to as a “stem”).


Modified Internucleotide Linkage: As used herein, the term “modified internucleotide linkage” refers to an internucleotide linkage having one or more chemical modifications compared with a reference internucleotide linkage comprising a phosphodiester bond. In some embodiments, a modified nucleotide is a non-naturally occurring linkage. Typically, a modified internucleotide linkage confers one or more desirable properties to a nucleic acid in which the modified internucleotide linkage is present. For example, a modified nucleotide may improve thermal stability, resistance to degradation, nuclease resistance, solubility, bioavailability, bioactivity, reduced immunogenicity, etc.


Modified Nucleotide: As used herein, the term “modified nucleotide” refers to a nucleotide having one or more chemical modifications compared with a corresponding reference nucleotide selected from: adenine ribonucleotide, guanine ribonucleotide, cytosine ribonucleotide, uracil ribonucleotide, adenine deoxyribonucleotide, guanine deoxyribonucleotide, cytosine deoxyribonucleotide and thymidine deoxyribonucleotide. In some embodiments, a modified nucleotide is a non-naturally occurring nucleotide. In some embodiments, a modified nucleotide has one or more chemical modifications in its sugar, nucleobase and/or phosphate group. In some embodiments, a modified nucleotide has one or more chemical moieties conjugated to a corresponding reference nucleotide. Typically, a modified nucleotide confers one or more desirable properties to a nucleic acid in which the modified nucleotide is present. For example, a modified nucleotide may improve thermal stability, resistance to degradation, nuclease resistance, solubility, bioavailability, bioactivity, reduced immunogenicity, etc. In certain embodiments, a modified nucleotide comprises a 2′-O-methyl or a 2′-F substitution at the 2′ position of the ribose ring.


Nicked Tetraloop Structure: A “nicked tetraloop structure” is a structure of a RNAi oligonucleotide characterized by the presence of separate sense (passenger) and antisense (guide) strands, in which the sense strand has a region of complementarity to the antisense strand such that the two strands form a duplex, and in which at least one of the strands, generally the sense strand, extends from the duplex in which the extension contains a tetraloop and two self-complementary sequences forming a stem region adjacent to the tetraloop, in which the tetraloop is configured to stabilize the adjacent stem region formed by the self-complementary sequences of the at least one strand.


Oligonucleotide: As used herein, the term “oligonucleotide” refers to a short nucleic acid, e.g., of less than 100 nucleotides in length. An oligonucleotide can comprise ribonucleotides, deoxyribonucleotides, and/or modified nucleotides including, for example, modified ribonucleotides. An oligonucleotide may be single-stranded or double-stranded. An oligonucleotide may or may not have duplex regions. As a set of non-limiting examples, an oligonucleotide may be, but is not limited to, a small interfering RNA (siRNA), microRNA (miRNA), short hairpin RNA (shRNA), dicer substrate interfering RNA (dsiRNA), antisense oligonucleotide, short siRNA, or single-stranded siRNA. In some embodiments, a double-stranded oligonucleotide is an RNAi oligonucleotide.


Overhang: As used herein, the term “overhang” refers to terminal non-base-pairing nucleotide(s) resulting from one strand or region extending beyond the terminus of a complementary strand with which the one strand or region forms a duplex. In some embodiments, an overhang comprises one or more unpaired nucleotides extending from a duplex region at the 5′ terminus or 3′ terminus of a double-stranded oligonucleotide. In certain embodiments, the overhang is a 3′ or 5′ overhang on the antisense strand or sense strand of a double-stranded oligonucleotide.


Phosphate analog: As used herein, the term “phosphate analog” refers to a chemical moiety that mimics the electrostatic and/or steric properties of a phosphate group. In some embodiments, a phosphate analog is positioned at the 5′ terminal nucleotide of an oligonucleotide in place of a 5′-phosphate, which is often susceptible to enzymatic removal. In some embodiments, a 5′ phosphate analog contains a phosphatase-resistant linkage. Examples of phosphate analogs include 5′ phosphonates, such as 5′ methylenephosphonate (5′-MP) and 5′-(E)-vinylphosphonate (5′-VP). In some embodiments, an oligonucleotide has a phosphate analog at a 4′-carbon position of the sugar (referred to as a “4′-phosphate analog”) at a 5′-terminal nucleotide. An example of a 4′-phosphate analog is oxymethylphosphonate, in which the oxygen atom of the oxymethyl group is bound to the sugar moiety (e.g., at its 4′-carbon) or analog thereof. See, e.g., PCT publication WO2018045317, filed on Sep. 1, 2017, U.S. Provisional Application numbers 62/383,207, filed on Sep. 2, 2016, and 62/393,401, filed on Sep. 12, 2016, the contents of each of which relating to phosphate analogs are incorporated herein by reference. Other modifications have been developed for the 5′ end of oligonucleotides (see, e.g., WO 2011/133871; U.S. Pat. No. 8,927,513; and Prakash et al., Nucleic Acids Res., 2015, 43(6):2993-3011, the contents of each of which relating to phosphate analogs are incorporated herein by reference).


Reduced expression: As used herein, the term “reduced expression” of a gene refers to a decrease in the amount of RNA transcript or protein encoded by the gene and/or a decrease in the amount of activity of the gene in a cell or subject, as compared to an appropriate reference cell or subject. For example, the act of treating a cell with a double-stranded oligonucleotide (e.g., one having an antisense strand that is complementary to ALDH2 mRNA sequence) may result in a decrease in the amount of RNA transcript, protein and/or enzymatic activity (e.g., encoded by the ALDH2 gene) compared to a cell that is not treated with the double-stranded oligonucleotide. Similarly, “reducing expression” as used herein refers to an act that results in reduced expression of a gene (e.g., ALDH2).


Region of Complementarity: As used herein, the term “region of complementarity” refers to a sequence of nucleotides of a nucleic acid (e.g., a double-stranded oligonucleotide) that is sufficiently complementary to an antiparallel sequence of nucleotides (e.g., a target nucleotide sequence within an mRNA) to permit hybridization between the two sequences of nucleotides under appropriate hybridization conditions, e.g., in a phosphate buffer, in a cell, etc. A region of complementarity may be fully complementary to a nucleotide sequence (e.g., a target nucleotide sequence present within an mRNA or portion thereof). For example, a region of complementary that is fully complementary to a nucleotide sequence present in an mRNA has a contiguous sequence of nucleotides that is complementary, without any mismatches or gaps, to a corresponding sequence in the mRNA. Alternatively, a region of complementarity may be partially complementary to a nucleotide sequence (e.g., a nucleotide sequence present in an mRNA or portion thereof). For example, a region of complementary that is partially complementary to a nucleotide sequence present in an mRNA has a contiguous sequence of nucleotides that is complementary to a corresponding sequence in the mRNA but that contains one or more mismatches or gaps (e.g., 1, 2, 3, or more mismatches or gaps) compared with the corresponding sequence in the mRNA, provided that the region of complementarity remains capable of hybridizing with the mRNA under appropriate hybridization conditions.


Ribonucleotide: As used herein, the term “ribonucleotide” refers to a nucleotide having a ribose as its pentose sugar, which contains a hydroxyl group at its 2′ position. A modified ribonucleotide is a ribonucleotide having one or more modifications or substitutions of atoms other than at the 2′ position, including modifications or substitutions in or of the ribose, phosphate group or base.


RNAi Oligonucleotide: As used herein, the term “RNAi oligonucleotide” refers to either (a) a double stranded oligonucleotide having a sense strand (passenger) and antisense strand (guide), in which the antisense strand or part of the antisense strand is used by the Argonaute 2 (Ago2) endonuclease in the cleavage of a target mRNA or (b) a single stranded oligonucleotide having a single antisense strand, where that antisense strand (or part of that antisense strand) is used by the Ago2 endonuclease in the cleavage of a target mRNA.


Strand: As used herein, the term “strand” refers to a single contiguous sequence of nucleotides linked together through internucleotide linkages (e.g., phosphodiester linkages, phosphorothioate linkages). In some embodiments, a strand has two free ends, e.g., a 5′-end and a 3′-end.


Subject: As used herein, the term “subject” means any mammal, including mice, rabbits, and humans. In one embodiment, the subject is a human or non-human primate. The terms “individual” or “patient” may be used interchangeably with “subject.”


Synthetic: As used herein, the term “synthetic” refers to a nucleic acid or other molecule that is artificially synthesized (e.g., using a machine (e.g., a solid-state nucleic acid synthesizer)) or that is otherwise not derived from a natural source (e.g., a cell or organism) that normally produces the molecule.


Targeting ligand: As used herein, the term “targeting ligand” refers to a molecule (e.g., a carbohydrate, amino sugar, cholesterol, polypeptide or lipid) that selectively binds to a cognate molecule (e.g., a receptor) of a tissue or cell of interest and that is conjugatable to another substance for purposes of targeting the other substance to the tissue or cell of interest. For example, in some embodiments, a targeting ligand may be conjugated to an oligonucleotide for purposes of targeting the oligonucleotide to a specific tissue or cell of interest. In some embodiments, a targeting ligand selectively binds to a cell surface receptor. Accordingly, in some embodiments, a targeting ligand when conjugated to an oligonucleotide facilitates delivery of the oligonucleotide into a particular cell through selective binding to a receptor expressed on the surface of the cell and endosomal internalization by the cell of the complex comprising the oligonucleotide, targeting ligand and receptor. In some embodiments, a targeting ligand is conjugated to an oligonucleotide via a linker that is cleaved following or during cellular internalization such that the oligonucleotide is released from the targeting ligand in the cell.


Tetraloop: As used herein, the term “tetraloop” refers to a loop that increases stability of an adjacent duplex formed by hybridization of flanking sequences of nucleotides. The increase in stability is detectable as an increase in melting temperature (Tm) of an adjacent stem duplex that is higher than the Tm of the adjacent stem duplex expected, on average, from a set of loops of comparable length consisting of randomly selected sequences of nucleotides. For example, a tetraloop can confer a melting temperature of at least 50° C., at least 55° C., at least 56° C., at least 58° C., at least 60° C., at least 65° C. or at least 75° C. in 10 mM NaHPO4 to a hairpin comprising a duplex of at least 2 base pairs in length. In some embodiments, a tetraloop may stabilize a base pair in an adjacent stem duplex by stacking interactions. In addition, interactions among the nucleotides in a tetraloop include but are not limited to non-Watson-Crick base-pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., Nature, 1990, 346(6285):680-2; Heus and Pardi, Science, 1991, 253(5016):191-4). In some embodiments, a tetraloop comprises or consists of 3 to 6 nucleotides and is typically 4 to 5 nucleotides. In certain embodiments, a tetraloop comprises or consists of three, four, five, or six nucleotides, which may or may not be modified (e.g., which may or may not be conjugated to a targeting moiety). In one embodiment, a tetraloop consists of four nucleotides. Any nucleotide may be used in the tetraloop and standard IUPAC-IUB symbols for such nucleotides may be used as described in Cornish-Bowden, Nucl. Acids Res., 1985, 13:3021-3030. For example, the letter “N” may be used to mean that any base may be in that position, the letter “R” may be used to show that A (adenine) or G (guanine) may be in that position, and “B” may be used to show that C (cytosine), G (guanine), or T (thymine) may be in that position. Examples of tetraloops include the UNCG family of tetraloops (e.g., UUCG), the GNRA family of tetraloops (e.g., GAAA), and the CUUG tetraloop (Woese et al., Proc Natl Acad Sci USA., 1990, 87(21):8467-71; Antao et al., Nucleic Acids Res., 1991, 19(21):5901-5). Examples of DNA tetraloops include the d(GNNA) family of tetraloops (e.g., d(GTTA)), the d(GNRA) family of tetraloops, the d(GNAB) family of tetraloops, the d(CNNG) family of tetraloops, and the d(TNCG) family of tetraloops (e.g., d(TTCG)). See, for example: Nakano et al., Biochemistry, 2002, 41 (48):14281-292; Shinji et al., Nippon Kagakkai Koen Yokoshu, 2000, 78(2):731, which are incorporated by reference herein for their relevant disclosures. In some embodiments, the tetraloop is contained within a nicked tetraloop structure.


Treat: As used herein, the term “treat” refers to the act of providing care to a subject in need thereof, e.g., through the administration a therapeutic agent (e.g., an oligonucleotide) to the subject, for purposes of improving the health and/or well-being of the subject with respect to an existing condition (e.g., a disease, disorder) or to prevent or decrease the likelihood of the occurrence of a condition. In some embodiments, treatment involves reducing the frequency or severity of at least one sign, symptom or contributing factor of a condition (e.g., disease, disorder) experienced by a subject.


II. Oligonucleotide-Based Inhibitors

i. ALDH2 Targeting Oligonucleotides


Oligonucleotides potent in the CNS are provided herein that were identified through examination of the ALDH2 mRNA, including mRNAs of multiple different species (human, cynomolgus monkey, and mouse), and in vitro and in vivo testing. As described herein, such oligonucleotides can be used to achieve therapeutic benefit for subjects having neurological diseases (e.g., neurodegenerative diseases, cognitive disorders, or anxiety disorders) by reducing gene activity (e.g., in the central nervous system), in this case the activity of ALDH2. Other genes that could be targeted with the methods and oligonucleotides of the current invention include those identified as causing: Spinocerebellar Ataxia Type 1 (Ataxin-1, and/or Ataxin-3); the β-amyloid precursor protein gene (APP or BACE1) or mutants thereof; Dystonia (DYT1); Amyotrophic Lateral Sclerosis “ALS” or Lou Gehrig's Disease (SOD1), and various genes that lead to tumors in the CNS. For example, potent RNAi oligonucleotides are provided herein that have a sense strand comprising, or consisting of, a sequence as set forth in any one of SEQ ID NO: 581-590, 608, and 609 and an antisense strand comprising, or consisting of, a complementary sequence selected from SEQ ID NO: 591-600, as is also arranged the table provided in Appendix A (e.g., a sense strand comprising a sequence as set forth in SEQ ID NO: 585 and an antisense strand comprising a sequence as set forth in SEQ ID NO: 595).


The sequences can be put into multiple different oligonucleotide structures (or formats). For example, in some embodiments, the sequences can be incorporated into oligonucleotides that comprise sense and antisense strands that are both in the range of 17 to 36 nucleotides in length. In some embodiments, oligonucleotides incorporating such sequences are provided that have a tetraloop structure within a 3′ extension of their sense strand, and two terminal overhang nucleotides at the 3′ end of its antisense strand. In some embodiments, the two terminal overhang nucleotides are GG. Typically, one or both of the two terminal GG nucleotides of the antisense strand is or are not complementary to the target.


In some embodiments, oligonucleotides incorporating such sequences are provided that have sense and antisense strands that are both in the range of 21 to 23 nucleotides in length. In some embodiments, a 3′ overhang is provided on the sense, antisense, or both sense and antisense strands that is 1 or 2 nucleotides in length. In some embodiments, an oligonucleotide has a guide strand of 23 nucleotides and a passenger strand of 21 nucleotides, in which the 3′-end of passenger strand and 5′-end of guide strand form a blunt end and where the guide strand has a two nucleotide 3′ overhang. In some embodiments, a 3′ overhang is provided on the antisense strand that is 9 nucleotides in length. For example, an oligonucleotide provided herein may have a guide strand of 22 nucleotides and a passenger strand of 29 nucleotides, wherein the passenger strand forms a tetraloop structure at the 3′ end and the guide strand has a 9 nucleotide 3′ overhang (herein termed “N-9”).


In some embodiments, it has been discovered that certain regions of ALDH2 mRNA are hotspots for targeting because they are more amenable than other regions to oligonucleotide-based inhibition. In some embodiments, a hotspot region of ALDH2 comprises, or consists of, a sequence as forth in any one of SEQ ID NOs: 601-607. These regions of ALDH2 mRNA may be targeted using oligonucleotides as discussed herein for purposes of inhibiting ALDH2 mRNA expression.


Accordingly, in some embodiments, oligonucleotides provided herein are designed to have regions of complementarity to ALDH2 mRNA (e.g., within a hotspot of ALDH2 mRNA) for purposes of targeting the mRNA in cells and inhibiting its expression. The region of complementarity is generally of a suitable length and base content to enable annealing of the oligonucleotide (or a strand thereof) to ALDH2 mRNA for purposes of inhibiting its expression.


In some embodiments, an oligonucleotide disclosed herein comprises a region of complementarity (e.g., on an antisense strand of a double-stranded oligonucleotide) that is at least partially complementary to a sequence of interest in a target gene. According to the current invention such sequences are as set forth in SEQ ID NOs: 1-14 and 17-290, which include sequences mapping to within hotspot regions of ALDH2 mRNA. In some embodiments, an oligonucleotide disclosed herein comprises a region of complementarity (e.g., on an antisense strand of a double-stranded oligonucleotide) that is fully complementary to a sequence as set forth in SEQ ID NOs: 1-14 and 17-290. In some embodiments, a region of complementarity of an oligonucleotide that is complementary to contiguous nucleotides of a sequence as set forth in SEQ ID NOs: 1-14 and 17-290 spans the entire length of an antisense strand. In some embodiments, a region of complementarity of an oligonucleotide that is complementary to contiguous nucleotides of a sequence as set forth in any one of SEQ ID NOs: 1-14 and 17-290 spans a portion of the entire length of an antisense strand (e.g., all but two nucleotides at the 3′ end of the antisense strand). In some embodiments, an oligonucleotide disclosed herein comprises a region of complementarity (e.g., on an antisense strand of a double-stranded oligonucleotide) that is at least partially (e.g., fully) complementary to a contiguous stretch of nucleotides spanning nucleotides 1-19 of a sequence as set forth in SEQ ID NOs: 581-590.


In some embodiments, the region of complementarity is at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25 nucleotides in length. In some embodiments, an oligonucleotide provided herein has a region of complementarity to ALDH2 that is in the range of 12 to 30 (e.g., 12 to 30, 12 to 22, 15 to 25, 17 to 21, 18 to 27, 19 to 27, or 15 to 30) nucleotides in length. In some embodiments, an oligonucleotide provided herein has a region of complementarity to ALDH2 that is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length.


In some embodiments, a region of complementarity to ALDH2 may have one or more mismatches compared with a corresponding sequence of ALDH2 mRNA. A region of complementarity on an oligonucleotide may have up to 1, up to 2, up to 3, up to 4, up to 5, etc., mismatches provided that it maintains the ability to form complementary base pairs with ALDH2 mRNA under appropriate hybridization conditions. Alternatively, a region of complementarity on an oligonucleotide may have no more than 1, no more than 2, no more than 3, no more than 4, or no more than 5 mismatches provided that it maintains the ability to form complementary base pairs with ALDH2 mRNA under appropriate hybridization conditions. In some embodiments, if there are more than one mismatches in a region of complementarity, they may be positioned consecutively (e.g., 2, 3, 4, or more in a row), or interspersed throughout the region of complementarity provided that the oligonucleotide maintains the ability to form complementary base pairs with ALDH2 mRNA under appropriate hybridization conditions.


In some embodiments, double-stranded oligonucleotides provided herein comprise, or consist of, a sense strand having a sequence as set forth in any one of SEQ ID NO: 1-14 and 17-290 and an antisense strand comprising a complementary sequence selected from SEQ ID NO: 291-304 and 307-580, as is arranged in the table provided in Appendix A (e.g., a sense strand comprising a sequence as set forth in SEQ ID NO: 1 and an antisense strand comprising a sequence as set forth in SEQ ID NO: 291).


ii. Oligonucleotide Structures


There are a variety of structures of oligonucleotides that are useful for targeting ALDH2 in the methods of the present disclosure, including RNAi, miRNA, etc. Any of the structures described herein or elsewhere may be used as a framework to incorporate or target a sequence described herein (e.g., a hotpot sequence of ALDH2 such as those illustrated in SEQ ID NOs: 601-607). Double-stranded oligonucleotides for targeting ALDH2 expression (e.g., via the RNAi pathway) generally have a sense strand and an antisense strand that form a duplex with one another. In some embodiments, the sense and antisense strands are not covalently linked. However, in some embodiments, the sense and antisense strands are covalently linked.


In some embodiments, double-stranded oligonucleotides for reducing the expression of ALDH2 expression engage RNA interference (RNAi). For example, RNAi oligonucleotides have been developed with each strand having sizes of 19-25 nucleotides with at least one 3′ overhang of 1 to 5 nucleotides (see, e.g., U.S. Pat. No. 8,372,968). Longer oligonucleotides have also been developed that are processed by Dicer to generate active RNAi products (see, e.g., U.S. Pat. No. 8,883,996). Further work produced extended double-stranded oligonucleotides where at least one end of at least one strand is extended beyond a duplex targeting region, including structures where one of the strands includes a thermodynamically-stabilizing tetraloop structure (see, e.g., U.S. Pat. Nos. 8,513,207 and 8,927,705, as well as WO2010033225, which are incorporated by reference herein for their disclosure of these oligonucleotides). Such structures may include single-stranded extensions (on one or both sides of the molecule) as well as double-stranded extensions.


In some embodiments, oligonucleotides may be in the range of 21 to 23 nucleotides in length. In some embodiments, oligonucleotides may have an overhang (e.g., of 1, 2, or 3 nucleotides in length) in the 3′ end of the sense and/or antisense strands. In some embodiments, oligonucleotides (e.g., siRNAs) may comprise a 21-nucleotide guide strand that is antisense to a target RNA and a complementary passenger strand, in which both strands anneal to form a 19-bp duplex and 2 nucleotide overhangs at either or both 3′ ends. In some embodiments, oligonucleotides (e.g., siRNAs) may comprise a 22-nucleotide guide strand that is antisense to a target RNA and a complementary passenger strand, in which both strands anneal to form a 13-bp duplex and 9 nucleotide overhangs at either or both 3′ ends. See, for example, U.S. Pat. Nos. 9,012,138; 9,012,621, and 9,193,753, the contents of each of which are incorporated herein for their relevant disclosures.


In some embodiments, an oligonucleotide of the invention has a 36-nucleotide sense strand that comprises a region extending beyond the antisense-sense duplex, where the extension region has a stem-tetraloop structure where the stem is a six base pair duplex and where the tetraloop has four nucleotides. In certain of those embodiments, three or four of the tetraloop nucleotides are each conjugated to a monovalent GalNac ligand. In certain of those embodiments, all of the tetraloop nucleotides are each conjugated to a monovalent GalNac ligand.


In some embodiments, an oligonucleotide of the invention comprises a 25-nucleotide sense strand and a 27-nucleotide antisense strand that when acted upon by a dicer enzyme results in an antisense strand that is incorporated into the mature RISC.


Other oligonucleotide designs for use with the compositions and methods are disclosed herein include: 16-mer siRNAs (see, e.g., Nucleic Acids in Chemistry and Biology. Blackburn (ed.), Royal Society of Chemistry, 2006), shRNAs (e.g., having 19 bp or shorter stems; see, e.g., Moore et al., Methods Mol. Biol., 2010, 629:141-158), blunt siRNAs (e.g., of 19 bps in length; see, e.g., Kraynack and Baker, R N A, 2006, 12:163-176), asymmetrical siRNAs (aiRNA; see, e.g., Sun et al., Nat. Biotechnol., 2008, 26:1379-1382), asymmetric shorter-duplex siRNA (see, e.g., Chang et al., Mol Ther., 2009, 17(4):725-32), fork siRNAs (see, e.g., Hohjoh, FEBS Letters, 2004, 557(1-3):193-198), single-stranded siRNAs (Elsner et al., Nature Biotechnology, 2012, 30:1063), dumbbell-shaped circular siRNAs (see, e.g., Abe et al., J Am Chem Soc., 2007, 129:15108-15109), and small internally segmented interfering RNA (sisiRNA; see, e.g., Bramsen et al., Nucleic Acids Res., 2007, 35(17):5886-5897). Each of the foregoing references is incorporated by reference in its entirety for the related disclosures therein. Further non-limiting examples of an oligonucleotide structures that may be used in some embodiments to reduce or inhibit the expression of ALDH2 are microRNA (miRNA), short hairpin RNA (shRNA), and short siRNA (see, e.g., Hamilton et al., EMBO J., 2002, 21(17):4671-4679; see also U.S. Application No. 20090099115).


a. Antisense Strands


In some embodiments, an oligonucleotide disclosed herein for targeting ALDH2 comprises an antisense strand comprising or consisting of a sequence as set forth in any one of SEQ ID NOs: 291-304, 307-580 and 591-600. In some embodiments, an oligonucleotide comprises an antisense strand comprising or consisting of at least 12 (e.g., at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) contiguous nucleotides of a sequence as set forth in any one of SEQ ID NOs: 291-304, 307-580 and 591-600.


In some embodiments, a double-stranded oligonucleotide may have an antisense strand of up to 40 nucleotides in length (e.g., up to 40, up to 35, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, an oligonucleotide may have an antisense strand of at least 12 nucleotides in length (e.g., at least 12, at least 15, at least 19, at least 21, at least 25, at least 27, at least 30, at least 35, or at least 38 nucleotides in length). In some embodiments, an oligonucleotide may have an antisense strand in a range of 12 to 40 (e.g., 12 to 40, 12 to 36, 12 to 32, 12 to 28, 15 to 40, 15 to 36, 15 to 32, 15 to 28, 17 to 21, 17 to 25, 19 to 27, 19 to 30, 20 to 40, 22 to 40, 25 to 40, or 32 to 40) nucleotides in length. In some embodiments, an oligonucleotide may have an antisense strand in a range of 19-27 (e.g., 19 to 27, 19-25, 19-23, 19-21, 21-27, 21-25, 21-23, 23-27, 23-25, or 25-27) nucleotides in length. In some embodiments, an oligonucleotide may have an antisense strand of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.


In some embodiments, an antisense strand of an oligonucleotide may be referred to as a “guide strand.” For example, if an antisense strand can engage with RNA-induced silencing complex (RISC) and bind to an Argonaut protein, or engage with or bind to one or more similar factors, and direct silencing of a target gene, it may be referred to as a guide strand. In some embodiments, a sense strand complementary to a guide strand may be referred to as a “passenger strand.”


b. Sense Strands


In some embodiments, an oligonucleotide disclosed herein for targeting ALDH2 comprises or consists of a sense strand sequence as set forth in any one of SEQ ID NOs: 1-14, 17-290, 581-590, 608, and 609. In some embodiments, an oligonucleotide has a sense strand that comprises or consists of at least 12 (e.g., at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23) contiguous nucleotides of a sequence as set forth in any one of SEQ ID NOs: 1-14, 17-290, 581-590, 608, and 609.


In some embodiments, an oligonucleotide may have a sense strand (or passenger strand) of up to 40 nucleotides in length (e.g., up to 40, up to 35, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, an oligonucleotide may have a sense strand of at least 12 nucleotides in length (e.g., at least 12, at least 15, at least 19, at least 21, at least 25, at least 27, at least 30, at least 35, or at least 38 nucleotides in length). In some embodiments, an oligonucleotide may have a sense strand in a range of 12 to 40 (e.g., 12 to 40, 12 to 36, 12 to 32, 12 to 28, 15 to 40, 15 to 36, 15 to 32, 15 to 28, 17 to 21, 17 to 25, 19 to 27, 19 to 30, 20 to 40, 22 to 40, 25 to 40, or 32 to 40) nucleotides in length. In some embodiments, an oligonucleotide may have a sense strand of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.


In some embodiments, a sense strand comprises a stem-loop structure at its 3′-end. In some embodiments, a sense strand comprises a stem-loop structure at its 5′-end. In some embodiments, a stem is a duplex of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 nucleotides in length. In some embodiments, a stem-loop provides the molecule better protection against degradation (e.g., enzymatic degradation) and facilitates targeting characteristics for delivery to a target cell. For example, in some embodiments, a loop provides added nucleotides on which modification can be made without substantially affecting the gene expression inhibition activity of an oligonucleotide. In certain embodiments, an oligonucleotide is provided herein in which the sense strand comprises (e.g., at its 3′-end) a stem-loop set forth as: S1-L-S2, in which S1 is complementary to S2, and in which L forms a loop between S1 and S2 of up to 10 nucleotides in length (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length).


In some embodiments, a loop (L) of a stem-loop is a tetraloop (e.g., within a nicked tetraloop structure). A tetraloop may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Typically, a tetraloop has 4 to 5 nucleotides. In some embodiments, the loop (L) comprises a sequence set forth as GAAA.


c. Duplex Length


In some embodiments, a duplex formed between a sense and antisense strand is at least 12 (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21) nucleotides in length. In some embodiments, a duplex formed between a sense and antisense strand is in the range of 12-30 nucleotides in length (e.g., 12 to 30, 12 to 27, 12 to 22, 15 to 25, 18 to 30, 18 to 22, 18 to 25, 18 to 27, 18 to 30, 19 to 30 or 21 to 30 nucleotides in length). In some embodiments, a duplex formed between a sense and antisense strand is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. In some embodiments a duplex formed between a sense and antisense strand does not span the entire length of the sense strand and/or antisense strand. In some embodiments, a duplex between a sense and antisense strand spans the entire length of either the sense or antisense strands. In certain embodiments, a duplex between a sense and antisense strand spans the entire length of both the sense strand and the antisense strand.


d. Oligonucleotide Ends


In some embodiments, an oligonucleotide provided herein comprises sense and antisense strands, such that there is a 3′-overhang on either the sense strand or the antisense strand, or both the sense and antisense strand. In some embodiments, oligonucleotides provided herein have one 5′ end that is thermodynamically less stable compared to the other 5′ end. In some embodiments, an asymmetric oligonucleotide is provided that includes a blunt end at the 3′ end of a sense strand and an overhang at the 3′ end of an antisense strand. In some embodiments, a 3′ overhang on an antisense strand is 1-8 nucleotides in length (e.g., 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides in length).


Typically, an oligonucleotide for RNAi has a two-nucleotide overhang on the 3′ end of the antisense (guide) strand. However, other overhangs are possible. In some embodiments, an overhang is a 3′ overhang comprising a length of between one and six nucleotides, optionally one to five, one to four, one to three, one to two, two to six, two to five, two to four, two to three, three to six, three to five, three to four, four to six, four to five, five to six nucleotides, or one, two, three, four, five or six nucleotides. However, in some embodiments, the overhang is a 5′ overhang comprising a length of between one and six nucleotides, optionally one to five, one to four, one to three, one to two, two to six, two to five, two to four, two to three, three to six, three to five, three to four, four to six, four to five, five to six nucleotides, or one, two, three, four, five or six nucleotides.


In some embodiments, an oligonucleotide of the present disclosure has a nine nucleotide overhang on the 3′ end of the antisense (guide) strand (referred to herein as “N9”). An exemplary N9 oligonucleotide comprises a sense strand having a sequence set forth in SEQ ID NO: 608 and an antisense strand having a sequence set forth in SEQ ID NO: 595.


In some embodiments, one or more (e.g., 2, 3, 4) terminal nucleotides of the 3′ end or 5′ end of a sense and/or antisense strand are modified. For example, in some embodiments, one or two terminal nucleotides of the 3′ end of an antisense strand are modified. In some embodiments, the last nucleotide at the 3′ end of an antisense strand is modified, e.g., comprises 2′-modification, such as a 2′-O-methoxyethyl. In some embodiments, the last one or two terminal nucleotides at the 3′ end of an antisense strand are complementary to the target. In some embodiments, the last one or two nucleotides at the 3′ end of the antisense strand are not complementary to the target. In some embodiments, the 5′ end and/or the 3′ end of a sense or antisense strand has an inverted cap nucleotide.


e. Mismatches


In some embodiments, the oligonucleotide has one or more (e.g., 1, 2, 3, 4, 5) mismatches between a sense and antisense strand. If there is more than one mismatch between a sense and antisense strand, they may be positioned consecutively (e.g., 2, 3 or more in a row), or interspersed throughout the region of complementarity. In some embodiments, the 3′-terminus of the sense strand contains one or more mismatches. In one embodiment, two mismatches are incorporated at the 3′ terminus of the sense strand. In some embodiments, base mismatches or destabilization of segments at the 3′-end of the sense strand of the oligonucleotide improved the potency of synthetic duplexes in RNAi, possibly through facilitating processing by Dicer.


iii. Single-Stranded Oligonucleotides


In some embodiments, an oligonucleotide for reducing ALDH2 expression as described herein is single-stranded. Such structures may include but are not limited to single-stranded RNAi oligonucleotides. Recent efforts have demonstrated the activity of single-stranded RNAi oligonucleotides (see, e.g., Matsui et al., Molecular Therapy, 2016, 24(5):946-955). However, in some embodiments, oligonucleotides provided herein are antisense oligonucleotides (ASOs). An antisense oligonucleotide is a single-stranded oligonucleotide that has a nucleobase sequence which, when written in the 5′ to 3′ direction, comprises the reverse complement of a targeted segment of a particular nucleic acid and is suitably modified (e.g., as a gapmer) so as to induce RNaseH mediated cleavage of its target RNA in cells or (e.g., as a mixmer) so as to inhibit translation of the target mRNA in cells. Antisense oligonucleotides for use in the instant disclosure may be modified in any suitable manner known in the art including, for example, as shown in U.S. Pat. No. 9,567,587, which is incorporated by reference herein for its disclosure regarding modification of antisense oligonucleotides (including, e.g., length, sugar moieties of the nucleobase (pyrimidine, purine), and alterations of the heterocyclic portion of the nucleobase). Further, antisense molecules have been used for decades to reduce expression of specific target genes (see, e.g., Bennett et al., Pharmacology of Antisense Drugs, Annual Review of Pharmacology and Toxicology, 2017, 57:81-105).


iv. Oligonucleotide Modifications


Oligonucleotides may be modified in various ways to improve or control specificity, stability, delivery, bioavailability, resistance from nuclease degradation, immunogenicity, base-paring properties, RNA distribution and cellular uptake and other features relevant to therapeutic or research use. See, e.g., Bramsen et al., Nucleic Acids Res., 2009, 37:2867-2881; Bramsen and Kjems, Frontiers in Genetics, 2012, 3:1-22). Accordingly, in some embodiments, oligonucleotides of the present disclosure may include one or more suitable modifications. In some embodiments, a modified nucleotide has a modification in its base (or nucleobase), the sugar (e.g., ribose, deoxyribose), or the phosphate group.


The number of modifications on an oligonucleotide and the positions of those nucleotide modifications may influence the properties of an oligonucleotide. For example, oligonucleotides may be delivered in vivo by conjugating them to or encompassing them in a lipid nanoparticle (LNP) or similar carrier. However, when an oligonucleotide is not protected by an LNP or similar carrier (e.g., “naked delivery”), it may be advantageous for at least some of the nucleotides to be modified. Accordingly, in certain embodiments of any of the oligonucleotides provided herein, all or substantially all the nucleotides of an oligonucleotide are modified. In certain embodiments, more than half of the nucleotides are modified. In certain embodiments, less than half of the nucleotides are modified. Typically, with naked delivery, every sugar is modified at the 2′-position. These modifications may be reversible or irreversible. In some embodiments, an oligonucleotide as disclosed herein has a number and type of modified nucleotides sufficient to cause the desired characteristic (e.g., protection from enzymatic degradation, capacity to target a desired cell after in vivo administration, and/or thermodynamic stability).


a. Sugar Modifications


In some embodiments, a modified sugar (also referred to herein as a sugar analog) includes a modified deoxyribose or ribose moiety, e.g., in which one or more modifications occur at the 2′, 3′, 4′, and/or 5′ carbon position of the sugar. In some embodiments, a modified sugar may also include non-natural alternative carbon structures such as those present in locked nucleic acids (“LNA”) (see, e.g., Koshkin et al., Tetrahedron, 1998, 54:3607-3630), unlocked nucleic acids (“UNA”) (see, e.g., Snead et al., Molecular Therapy—Nucleic Acids, 2013, 2:e103), and bridged nucleic acids (“BNA”) (see, e.g., Imanishi and Obika, The Royal Society of Chemistry, Chem. Commun., 2002, 1653-1659); Koshkin et al., Snead et al., and Imanishi and Obika are incorporated by reference herein for their disclosures relating to sugar modifications.


In some embodiments, a nucleotide modification in a sugar comprises a 2′-modification. In certain embodiments, the 2′-modification may be 2′-aminoethyl, 2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl, or 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid. Typically, the modification is 2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl, 2′-adem, or 2′-aminodiethoxymethanol. However, a large variety of 2′ position modifications that have been developed for use in oligonucleotides can be employed in oligonucleotides disclosed herein. See, e.g., Bramsen et al., Nucleic Acids Res., 2009, 37:2867-2881. In some embodiments, a modification in a sugar comprises a modification of the sugar ring, which may comprise modification of one or more carbons of the sugar ring. For example, a modification of a sugar of a nucleotide may comprise a linkage between the 2′-carbon and a 1′-carbon or 4′-carbon of the sugar. For example, the linkage may comprise an ethylene or methylene bridge. In some embodiments, a modified nucleotide has an acyclic sugar that lacks a 2′-carbon to 3′-carbon bond. In some embodiments, a modified nucleotide has a thiol group, e.g., in the 4′ position of the sugar.


In some embodiments, the terminal 3′-end group (e.g., a 3′-hydroxyl) is a phosphate group or other group, which can be used, for example, to attach linkers, adapters or labels or for the direct ligation of an oligonucleotide to another nucleic acid.


b. 5′ Terminal Phosphates


5′-terminal phosphate groups of oligonucleotides may or in some circumstances enhance the interaction with Argonaut 2. However, oligonucleotides comprising a 5′-phosphate group may be susceptible to degradation via phosphatases or other enzymes, which can limit their bioavailability in vivo. In some embodiments, oligonucleotides include analogs of 5′ phosphates that are resistant to such degradation. In some embodiments, a phosphate analog may be oxymethylphosphonate, vinylphosphonate, or malonylphosphonate. In certain embodiments, the 5′ end of an oligonucleotide strand is attached to a chemical moiety that mimics the electrostatic and steric properties of a natural 5′-phosphate group (“phosphate mimic”) (see, e.g., Prakash et al., Nucleic Acids Res., 2015, 43(6):2993-3011, the contents of which relating to phosphate analogs are incorporated herein by reference). Many phosphate mimics have been developed that can be attached to the 5′ end (see, e.g., U.S. Pat. No. 8,927,513, the contents of which relating to phosphate analogs are incorporated herein by reference). Other modifications have been developed for the 5′ end of oligonucleotides (see, e.g., WO 2011/133871, the contents of which relating to phosphate analogs are incorporated herein by reference). In certain embodiments, a hydroxyl group is attached to the 5′ end of the oligonucleotide.


In some embodiments, an oligonucleotide has a phosphate analog at a 4′-carbon position of the sugar (referred to as a “4′-phosphate analog”). See, for example, International Patent publication WO2018045317; U.S. Provisional Application numbers 62/383,207, entitled 4′-Phosphate Analogs and Oligonucleotides Comprising the Same, filed on Sep. 2, 2016, and 62/393,401, filed on Sep. 12, 2016, entitled 4′-Phosphate Analogs and Oligonucleotides Comprising the Same, the contents of each of which relating to phosphate analogs are incorporated herein by reference. In some embodiments, an oligonucleotide provided herein comprises a 4′-phosphate analog at a 5′-terminal nucleotide. In some embodiments, a phosphate analog is an oxymethylphosphonate, in which the oxygen atom of the oxymethyl group is bound to the sugar moiety (e.g., at its 4′-carbon) or analog thereof. In other embodiments, a 4′-phosphate analog is a thiomethylphosphonate or an aminomethylphosphonate, in which the sulfur atom of the thiomethyl group or the nitrogen atom of the aminomethyl group is bound to the 4′-carbon of the sugar moiety or analog thereof. In certain embodiments, a 4′-phosphate analog is an oxymethylphosphonate. In some embodiments, an oxymethylphosphonate is represented by the formula —O—CH2—PO(OH)2 or —O—CH2—PO(OR)2, in which R is independently selected from H, CH3, an alkyl group, CH2CH2CN, CH2OCOC(CH3)3, CH2OCH2CH2S1 (CH3)3, or a protecting group. In certain embodiments, the alkyl group is CH2CH3. More typically, R is independently selected from H, CH3, or CH2CH3.


c. Modified Internucleoside Linkages


In some embodiments, the oligonucleotide may comprise a modified internucleoside linkage. In some embodiments, phosphate modifications or substitutions may result in an oligonucleotide that comprises at least one (e.g., at least 1, at least 2, at least 3 or at least 5) modified internucleotide linkage. In some embodiments, any one of the oligonucleotides disclosed herein comprises 1 to 12 (e.g., 1 to 12, 1 to 10, 2 to 10, 2 to 8, 4 to 6, 3 to 10, 5 to 10, 1 to 5, 1 to 3 or 1 to 2) modified internucleotide linkages. In some embodiments, any one of the oligonucleotides disclosed herein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified internucleotide linkages.


A modified internucleotide linkage may be a phosphorodithioate linkage, a phosphorothioate linkage, a phosphotriester linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a phosphoramidite linkage, a phosphonate linkage or a boranophosphate linkage. In some embodiments, at least one modified internucleotide linkage of any one of the oligonucleotides as disclosed herein is a phosphorothioate linkage.


In some embodiments, in the N9 oligonucleotides, each of the internucleoside linkage in the 9 nucleotide 3′ overhang is a modified internucleotide linkage (e.g., a phosphorothioate linkage).


d. Base Modifications


In some embodiments, oligonucleotides provided herein have one or more modified nucleobases. In some embodiments, modified nucleobases (also referred to herein as base analogs) are linked at the 1′ position of a nucleotide sugar moiety. In certain embodiments, a modified nucleobase is a nitrogenous base. In certain embodiments, a modified nucleobase does not contain a nitrogen atom. See, e.g., U.S. Published Patent Application No. 20080274462. In some embodiments, a modified nucleotide comprises a universal base. However, in certain embodiments, a modified nucleotide does not contain a nucleobase (abasic).


In some embodiments, a universal base is a heterocyclic moiety located at the 1′ position of a nucleotide sugar moiety in a modified nucleotide, or the equivalent position in a nucleotide sugar moiety substitution that, when present in a duplex, can be positioned opposite more than one type of base without substantially altering the structure of the duplex. In some embodiments, compared to a reference single-stranded nucleic acid (e.g., oligonucleotide) that is fully complementary to a target nucleic acid, a single-stranded nucleic acid containing a universal base forms a duplex with the target nucleic acid that has a lower Tm than a duplex formed with the complementary nucleic acid. However, in some embodiments, compared to a reference single-stranded nucleic acid in which the universal base has been replaced with a base to generate a single mismatch, the single-stranded nucleic acid containing the universal base forms a duplex with the target nucleic acid that has a higher Tm than a duplex formed with the nucleic acid comprising the mismatched base.


Non-limiting examples of universal-binding nucleotides include inosine, 1-β-D-ribofuranosyl-5-nitroindole, and/or 1-β-D-ribofuranosyl-3-nitropyrrole (US Pat. Appl. Publ. No. 20070254362 to Quay et al.; Van Aerschot et al., Nucleic Acids Res., 1995, 23(21):4363-70; Loakes et al., Nucleic Acids Res., 1995, 23(13):2361-6; Loakes and Brown, Nucleic Acids Res., 1994, 22(20):4039-43). Each of the foregoing is incorporated by reference herein for their disclosures relating to base modifications).


e. Reversible Modifications


While certain modifications to protect an oligonucleotide from the in vivo environment before reaching target cells can be made, they can reduce the potency or activity of the oligonucleotide once it reaches the cytosol of the target cell. Reversible modifications can be made such that the molecule retains desirable properties outside of the cell, which are then removed upon entering the cytosolic environment of the cell. Reversible modification can be removed, for example, by the action of an intracellular enzyme or by the chemical conditions inside of a cell (e.g., through reduction by intracellular glutathione).


In some embodiments, a reversibly modified nucleotide comprises a glutathione-sensitive moiety. Typically, nucleic acid molecules have been chemically modified with cyclic disulfide moieties to mask the negative charge created by the internucleotide diphosphate linkages and improve cellular uptake and nuclease resistance. See U.S. Published Application No. 2011/0294869 originally assigned to Traversa Therapeutics, Inc. (“Traversa”); PCT Publication No. WO 2015/188197 to Solstice Biologics, Ltd. (“Solstice”); Meade et al., Nature Biotechnology, 2014, 32:1256-1263; PCT Publication No. WO 2014/088920 to Merck Sharp & Dohme Corp.; each of which are incorporated by reference for their disclosures of such modifications. This reversible modification of the internucleotide diphosphate linkages is designed to be cleaved intracellularly by the reducing environment of the cytosol (e.g., glutathione). Earlier examples include neutralizing phosphotriester modifications that were reported to be cleavable inside cells (Dellinger et al., J. Am. Chem. Soc., 2003, 125:940-950).


In some embodiments, such a reversible modification allows protection during in vivo administration (e.g., transit through the blood and/or lysosomal/endosomal compartments of a cell) where the oligonucleotide will be exposed to nucleases and other harsh environmental conditions (e.g., pH). When released into the cytosol of a cell where the levels of glutathione are higher compared to extracellular space, the modification is reversed, and the result is a cleaved oligonucleotide. Using reversible, glutathione sensitive moieties, it is possible to introduce sterically larger chemical groups into the oligonucleotide of interest as compared to the options available using irreversible chemical modifications. This is because these larger chemical groups will be removed in the cytosol and, therefore, should not interfere with the biological activity of the oligonucleotides inside the cytosol of a cell. As a result, these larger chemical groups can be engineered to confer various advantages to the nucleotide or oligonucleotide, such as nuclease resistance, lipophilicity, charge, thermal stability, specificity, and reduced immunogenicity. In some embodiments, the structure of the glutathione-sensitive moiety can be engineered to modify the kinetics of its release.


In some embodiments, a glutathione-sensitive moiety is attached to the sugar of the nucleotide. In some embodiments, a glutathione-sensitive moiety is attached to the 2′-carbon of the sugar of a modified nucleotide. In some embodiments, the glutathione-sensitive moiety is located at the 5′-carbon of a sugar, particularly when the modified nucleotide is the 5′-terminal nucleotide of the oligonucleotide. In some embodiments, the glutathione-sensitive moiety is located at the 3′-carbon of a sugar, particularly when the modified nucleotide is the 3′-terminal nucleotide of the oligonucleotide. In some embodiments, the glutathione-sensitive moiety comprises a sulfonyl group. See, e.g., PCT publication WO2018039364, and U.S. Provisional Application No. 62/378,635, entitled Compositions Comprising Reversibly Modified Oligonucleotides and Uses Thereof, filed on Aug. 23, 2016, the contents of which are incorporated by reference herein for its relevant disclosures.


v. Targeting Ligands


In some embodiments, it may be desirable to target the oligonucleotides of the disclosure to one or more cells or cell types of the CNS where reduction of mutant or toxic gene expression may provide clinical benefit. Such a strategy may help to avoid undesirable effects in other organs or cell types, or may avoid undue loss of the oligonucleotide to cells, tissue or organs that would not benefit from the inhibitory aspects of the oligonucleotide. Accordingly, in some embodiments, oligonucleotides disclosed herein may be modified to facilitate targeting of a particular tissue, cell or organ, e.g., to facilitate delivery of the oligonucleotide to the CNS. In some embodiments, an oligonucleotide comprises a nucleotide that is conjugated to one or more targeting ligands.


A targeting ligand may comprise a carbohydrate, amino sugar, cholesterol, peptide, polypeptide, protein or part of a protein (e.g., an antibody or antibody fragment) or lipid. In some embodiments, a targeting ligand is an aptamer. For example, a targeting ligand may be an RGD peptide that is used to target tumor vasculature or glioma cells, CREKA peptide to target tumor vasculature or stoma, transferrin, lactoferrin, or an aptamer to target transferrin receptors expressed on CNS vasculature, or an anti-EGFR antibody to target EGFR on glioma cells. In certain embodiments, the targeting ligand is one or more GalNAc moieties.


In some embodiments, 1 or more (e.g., 1, 2, 3, 4, 5 or 6) nucleotides of an oligonucleotide are each conjugated to a separate targeting ligand. In some embodiments, 2 to 4 nucleotides of an oligonucleotide are each conjugated to a separate targeting ligand. In some embodiments, targeting ligands are conjugated to 2 to 4 nucleotides at either ends of the sense or antisense strand (e.g., ligands are conjugated to a 2 to 4 nucleotide overhang or extension on the 5′ or 3′ end of the sense or antisense strand) such that the targeting ligands resemble bristles of a toothbrush and the oligonucleotide resembles a toothbrush. For example, an oligonucleotide may comprise a stem-loop at either the 5′ or 3′ end of the sense strand and 1, 2, 3 or 4 nucleotides of the loop of the stem may be individually conjugated to a targeting ligand, as described, for example, in International Patent Application Publication WO 2016/100401, the relevant contents of which are incorporated herein by reference.


In some embodiments, it is desirable to target an oligonucleotide that reduces the expression of ALDH2 to the cell of the CNS of a subject. GalNAc is a high affinity ligand for asialoglycoprotein receptor (ASGPR), which is primarily expressed on the sinusoidal surface of hepatocyte cells and has a major role in binding, internalization, and subsequent clearance of circulating glycoproteins that contain terminal galactose or N-acetylgalactosamine residues (asialoglycoproteins). In some embodiments, conjugation (either indirect or direct) of GalNAc moieties to oligonucleotides of the instant disclosure may be used to target these oligonucleotides to the ASGPR expressed on these hepatocyte cells. However, in some embodiments, GalNAc moieties may be used with oligonucleotides that are delivered directly to the CNS.


In some embodiments, an oligonucleotide of the instant disclosure is conjugated directly or indirectly to a monovalent GalNAc. In some embodiments, the oligonucleotide is conjugated directly or indirectly to more than one monovalent GalNAc (i.e., is conjugated to 2, 3, or 4 monovalent GalNAc moieties, and is typically conjugated to 3 or 4 monovalent GalNAc moieties). In some embodiments, an oligonucleotide of the instant disclosure is conjugated to one or more bivalent GalNAc, trivalent GalNAc, or tetravalent GalNAc moieties.


In some embodiments, 1 or more (e.g., 1, 2, 3, 4, 5 or 6) nucleotides of an oligonucleotide are each conjugated to a GalNAc moiety. In some embodiments, 2 to 4 nucleotides of the loop (L) of the stem-loop are each conjugated to a separate GalNAc. In some embodiments, targeting ligands are conjugated to 2 to 4 nucleotides at either ends of the sense or antisense strand (e.g., ligands are conjugated to a 2 to 4 nucleotide overhang or extension on the 5′ or 3′ end of the sense or antisense strand) such that the GalNAc moieties resemble bristles of a toothbrush and the oligonucleotide resembles a toothbrush. For example, an oligonucleotide may comprise a stem-loop at either the 5′ or 3′ end of the sense strand and 1, 2, 3 or 4 nucleotides of the loop of the stem may be individually conjugated to a GalNAc moiety. In some embodiments, GalNAc moieties are conjugated to a nucleotide of the sense strand. For example, four GalNAc moieties can be conjugated to nucleotides in the tetraloop of the sense strand, where each GalNAc moiety is conjugated to one nucleotide.


In some embodiments, an oligonucleotide herein comprises a monovalent GalNAc attached to a Guanidine nucleotide, referred to as [ademG-GalNAc] or 2′-aminodiethoxymethanol-Guanidine-GalNAc, as depicted below:




embedded image


In some embodiments, an oligonucleotide herein comprises a monovalent GalNAc attached to an adenine nucleotide, referred to as [ademA-GalNAc] or 2′-aminodiethoxymethanol-Adenine-GalNAc, as depicted below.




embedded image


An example of such conjugation is shown below for a loop comprising from 5′ to 3′ the nucleotide sequence GAAA (L=linker, X=heteroatom) stem attachment points are shown. In some embodiments, such a loop may be present, for example, at positions 27-30 of sense strand oligonucleotides 36 nucleotides in length, such as presented in Appendix A and as illustrated in FIG. 23. In the chemical formula,




embedded image


is used to describe an attachment point to the oligonucleotide strand.




embedded image


In some embodiments, L represents a bond, click chemistry handle, or a linker of 1 to 20, inclusive, consecutive, covalently bonded atoms in length, selected from the group consisting of substituted and unsubstituted alkylene, substituted and unsubstituted alkenylene, substituted and unsubstituted alkynylene, substituted and unsubstituted heteroalkylene, substituted and unsubstituted heteroalkenylene, substituted and unsubstituted heteroalkynylene, and combinations thereof; and X is O, S, or N. In some embodiments, L is an acetal linker. In some embodiments, X is O.


Appropriate methods or chemistry (e.g., click chemistry) can be used to link a targeting ligand to a nucleotide. In some embodiments, a targeting ligand is conjugated to a nucleotide using a click linker. In some embodiments, an acetal-based linker is used to conjugate a targeting ligand to a nucleotide of any one of the oligonucleotides described herein. Acetal-based linkers are disclosed, for example, in International patent publication WO2016100401, the contents of which relating to such linkers are incorporated herein by reference. In some embodiments, the linker is a labile linker. However, in other embodiments, the linker is stable. A “labile linker” refers to a linker that can be cleaved, e.g., by acidic pH. A “stable linker” refers to a linker that cannot be cleaved.


Another example is shown below for a loop comprising from 5′ to 3′ the nucleotides GAAA, in which GalNAc moieties are attached to nucleotides of the loop using an acetal linker. In some embodiments, such a loop may be present, for example, at positions 27-30 of sense strand oligonucleotides 36 nucleotides in length, such as presented in Appendix A, and as illustrated in FIG. 23. In the chemical formula,




embedded image


is an attachment point to the oligonucleotide strand.




embedded image


In some embodiments, the linker is a labile linker. However, in other embodiments, the linker is stable. In some embodiments, a duplex extension (up to 3, 4, 5, or 6 base pairs in length) is provided between a targeting ligand (e.g., a GalNAc moiety) and a double-stranded oligonucleotide.


In some embodiments, the GalNAc moiety is conjugated to each of A in the sequence GAAA, as illustrated in FIG. 23 for Conjugate A and Conjugate B. In some embodiments, the GalNAc moiety conjugated to each of A has the structure illustrated above, except that G is unmodified or has a 2′ modification on the sugar moiety. In some embodiments, the G in the GAAA sequence comprises a 2′ modification (e.g., 2′-O-methyl or 2′-O-methoxyethyl), and each of A in the GAAA sequence is conjugated to a GalNAc moiety, as illustrated in the structures above.


In some embodiments, the oligonucleotides of the present disclosure do not have a GalNAc conjugated. It was found herein that GalNAc conjugation is not required for neural cell uptake and oligonucleotide activity. In some embodiments, non-GalNAc-conjugated oligonucleotides have enhanced activity, compared to the GalNAc-conjugated counterparts.


vi. Oligonucleotide Derivatives


The present disclosure provides a range of oligonucleotide derivatives comprises a sense strand and an antisense strand, wherein the sense strand comprises a tetraloop comprising a L sequence set forth as GAAA, and wherein the sense strand and the antisense strand are not covalently linked. Different derivatives have different nucleotide modifications in the tetraloop.


In some embodiments, each of the A in GAAA sequence is conjugated to a GalNAc, and wherein the G in the GAAA sequence comprises a 2′-O-methyl modification. The oligonucleotide comprising this structure is termed herein as “Conjugate A.”


In some embodiments, each of the A in GAAA sequence and is conjugated to a GalNAc, and wherein the G in the GAAA sequence comprises a 2′-OH. The oligonucleotide comprising this structure is termed herein as “Conjugate B.”


In some embodiments, each of the nucleotides in the GAAA sequence is comprises a 2′-O-methyl modification. The oligonucleotide comprising this structure is termed herein as “Conjugate D.” Conjugate D does not have GalNAc conjugated to any of the nucleotides in the GAAA sequence.


In some embodiments, each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification. The oligonucleotide comprising this structure is termed herein as “Conjugate E.” Conjugate E does not have GalNAc conjugated to any of the nucleotides in the GAAA sequence.


In some embodiments, each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl (see, e.g., FIG. 23) modification and the G in the GAAA sequence comprises a 2′-O-methyl modification. The oligonucleotide comprising this structure is termed herein as “Conjugate F.” Conjugate F does not have GalNAc conjugated to any of the nucleotides in the GAAA sequence.


In some embodiments, each of the A in the GAAA sequence comprises a 2′-adem modification and the G in the GAAA sequence comprises a 2′-O-methyl modification. The oligonucleotide comprising this structure is termed herein as “Conjugate F.” Conjugate F does not have GalNAc conjugated to any of the nucleotides in the GAAA sequence.


In some embodiments, in any of the oligonucleotide derivatives described herein, the sense strand may comprise a sequence selected from SEQ ID NOs: 581-590 and the antisense strand may comprise a sequence selected from SEQ ID NOs: 591-600.


In some embodiments, the oligonucleotide derivative described herein comprises an antisense strand and a sense strand that are not covalently linked, wherein the antisense strand comprises a sequence as set forth in SEQ ID NO: 585 and the sense strand comprises a sequence as set forth in SEQ ID NO: 595, wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L is a tetraloop comprising a sequence set forth as GAAA, and wherein the GAAA sequence comprises a structure selected from the group consisting of:


(i) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-O-methyl modification;


(ii) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-OH;


(iii) each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification;


(iv) each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification;


(v) each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification; and


(vi) each of the A in the GAAA sequence comprises a 2′-adem modification and the G in the GAAA sequence comprises a 2′-O-methyl modification.


In some embodiments, the oligonucleotide derivative described herein does not comprise a tetraloop in the sense strand (e.g., the 3′ end of the sense strand and the 5′ end of the antisense strand form a blunt end and the sense strand and the antisense strand are not covalently linked). The oligonucleotide comprising this structure is termed herein as “Conjugate F.” An exemplary Conjugate F may comprise a sense strand having the sequence set forth in SEQ ID NO: 609 and an antisense sequence having the sequence as set forth in SEQ ID NO: 595, where the antisense strand and the sense strand are not covalently linked.


In some embodiments, the oligonucleotide derivatives described herein further comprises different arrangements of 2′-fluoro and 2′-O-methyl modified nucleotides, phophorothioate linkages, and/or included a phosphate analog positioned at the 5′ terminal nucleotide of their antisense strands III. Formulations


Various formulations have been developed to facilitate oligonucleotide use. For example, oligonucleotides can be delivered to a subject or a cellular environment using a formulation that minimizes degradation, facilitates delivery and/or uptake, or provides another beneficial property to the oligonucleotides in the formulation. In some embodiments, provided herein are compositions comprising oligonucleotides (e.g., single-stranded or double-stranded oligonucleotides) to reduce the expression of ALDH2. Such compositions can be suitably formulated such that when administered to a subject, either into the immediate environment of a target cell or systemically, a sufficient portion of the oligonucleotides enter the cell to reduce ALDH2 expression. Any of a variety of suitable oligonucleotide formulations can be used to deliver oligonucleotides for the reduction of ALDH2 as disclosed herein. In some embodiments, an oligonucleotide is formulated in buffer solutions such as phosphate-buffered saline solutions, liposomes, micellar structures, and capsids. In some embodiments, naked oligonucleotides or conjugates thereof are formulated in water or in an aqueous solution (e.g., water with pH adjustments). In some embodiments, naked oligonucleotides or conjugates thereof are formulated in basic buffered aqueous solutions (e.g., PBS).


Formulations of oligonucleotides with cationic lipids can be used to facilitate transfection of the oligonucleotides into cells. For example, cationic lipids, such as lipofectin, cationic glycerol derivatives, and polycationic molecules (e.g., polylysine) can be used. Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.), or FuGene 6 (Roche) all of which can be used according to the manufacturer's instructions.


Accordingly, in some embodiments, a formulation comprises a lipid nanoparticle. In some embodiments, an excipient comprises a liposome, a lipid, a lipid complex, a microsphere, a microparticle, a nanosphere, or a nanoparticle, or may be otherwise formulated for administration to the cells, tissues, organs, or body of a subject in need thereof (see, e.g., Remington: The Science and Practice of Pharmacy, 22nd edition, Pharmaceutical Press, 2013).


In some embodiments, the oligonucleotides are formulated with a pharmaceutically acceptable carrier, including excipients. In some embodiments, formulations as disclosed herein comprise an excipient or carrier. In some embodiments, an excipient or carrier confers to a composition improved stability, improved absorption, improved solubility and/or therapeutic enhancement of the active ingredient. In some embodiments, an excipient or carrier is a buffering agent (e.g., sodium citrate, sodium phosphate, a tris base, or sodium hydroxide) or a vehicle (e.g., a buffered solution, petrolatum, dimethyl sulfoxide, or mineral oil). In some embodiments, an oligonucleotide is lyophilized for extending its shelf-life and then made into a solution before use (e.g., administration to a subject). Accordingly, an excipient in a composition comprising any one of the oligonucleotides described herein may be a lyoprotectant (e.g., mannitol, lactose, polyethylene glycol, or polyvinyl pyrolidone), or a collapse temperature modifier (e.g., dextran, ficoll, or gelatin).


In some embodiments, a pharmaceutical composition is formulated to be compatible with its intended route of administration. The oligonucleotides of the present disclosure are administered to the cerebrospinal fluid of the subject. Suitable routes of administration include, without limitation, intraventricular, intracavitary, intrathecal, or interstitial administration.


Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous or subcutaneous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Sterile injectable solutions can be prepared by incorporating the oligonucleotides in a required amount in a selected solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.


In some embodiments, a composition may contain at least about 0.1% of the therapeutic agent (e.g., an oligonucleotide for reducing ALDH2 expression) or more, although the percentage of the active ingredient(s) may be between about 1% and about 80% or more of the weight or volume of the total composition. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.


IV. Methods of Use

i. Reducing ALDH2 Expression in Cells


In some embodiments, methods are provided for delivering to a cell an effective amount any one of oligonucleotides disclosed herein for purposes of reducing expression of ALDH2 in the cell. Methods provided herein are useful in any appropriate cell type. In some embodiments, a cell is any cell that expresses ALDH2 (e.g., hepatocytes, macrophages, monocyte-derived cells, prostate cancer cells, cells of the central nervous system (e.g., neurons or glial cells), endocrine tissue, bone marrow, lymph nodes, lung, gall bladder, liver, duodenum, small intestine, pancreas, kidney, gastrointestinal tract, bladder, adipose and soft tissue and skin). In some embodiments, the cell is a primary cell that has been obtained from a subject and that may have undergone a limited number of a passages, such that the cell substantially maintains its natural phenotypic properties. In some embodiments, a cell to which the oligonucleotide is delivered is ex vivo or in vitro (i.e., can be delivered to a cell in culture or to an organism in which the cell resides). In specific embodiments, methods are provided for delivering to a cell an effective amount any one of the oligonucleotides disclosed herein for purposes of reducing expression of ALDH2 solely in the central nervous system (CNS).


In some embodiments, oligonucleotides disclosed herein can be introduced using appropriate nucleic acid delivery methods including injection of a solution containing the oligonucleotides, bombardment by particles covered by the oligonucleotides, exposing the cell or organism to a solution containing the oligonucleotides, or electroporation of cell membranes in the presence of the oligonucleotides. Other appropriate methods for delivering oligonucleotides to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, and cationic liposome transfection such as calcium phosphate, and others.


The consequences of inhibition can be confirmed by an appropriate assay to evaluate one or more properties of a cell or subject, or by biochemical techniques that evaluate molecules indicative of ALDH2 expression (e.g., RNA, protein). In some embodiments, the extent to which an oligonucleotide provided herein reduces levels of expression of ALDH2 is evaluated by comparing expression levels (e.g., mRNA or protein levels of ALDH2 to an appropriate control (e.g., a level of ALDH2 expression in a cell or population of cells to which an oligonucleotide has not been delivered or to which a negative control has been delivered). In some embodiments, an appropriate control level of ALDH2 expression may be a predetermined level or value, such that a control level need not be measured every time. The predetermined level or value can take a variety of forms. In some embodiments, a predetermined level or value can be single cut-off value, such as a median or mean.


In some embodiments, administration of an oligonucleotide as described herein results in a reduction in the level of ALDH2 expression in a cell. In some embodiments, the reduction in levels of ALDH2 expression may be a reduction to 1% or lower, 5% or lower, 10% or lower, 15% or lower, 20% or lower, 25% or lower, 30% or lower, 35% or lower, 40% or lower, 45% or lower, 50% or lower, 55% or lower, 60% or lower, 70% or lower, 80% or lower, or 90% or lower compared with an appropriate control level of ALDH2. The appropriate control level may be a level of ALDH2 expression in a cell or population of cells that has not been contacted with an oligonucleotide as described herein. In some embodiments, the effect of delivery of an oligonucleotide to a cell according to a method disclosed herein is assessed after a finite period. For example, levels of ALDH2 may be analyzed in a cell at least 8 hours, 12 hours, 18 hours, 24 hours; or at least one, two, three, four, five, six, seven, or fourteen days after introduction of the oligonucleotide into the cell.


In some embodiments, an oligonucleotide is delivered in the form of a transgene that is engineered to express in a cell the oligonucleotides (e.g., its sense and antisense strands). In some embodiments, an oligonucleotide is delivered using a transgene that is engineered to express any oligonucleotide disclosed herein. Transgenes may be delivered using viral vectors (e.g., adenovirus, retrovirus, vaccinia virus, poxvirus, adeno-associated virus or herpes simplex virus) or non-viral vectors (e.g., plasmids or synthetic mRNAs). In some embodiments, transgenes can be injected directly to a subject.


ii. Treatment Methods


In another aspect, the present disclosure relates to methods for reducing ALDH2 expression for the treatment of a neurological disease in a subject. In some embodiments, the methods may comprise administering to the cerebrospinal fluid of a subject in need thereof an effective amount of any one of the oligonucleotides disclosed herein. Such treatments could be used, for example, to reduce ALDH2 expression in the central nervous system (e.g., somatosensory cortex, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, and across the spinal cord). The present disclosure provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a neurological disease. In some embodiments, the present disclosure provides methods or use of the oligonucleotides for treating a neurological disorder. In some embodiments, the neurological disorder is a neurodegenerative disease, cognitive disorder, or anxiety disorder. Exemplary neurological disorders associated with ALDH2 expression in the CNS include, among others, senile dementia, dyskinesia, Alzheimer's disease (AD), and Parkinson's disease (PD).


In certain aspects, the disclosure provides a method for preventing in a subject, a disease or disorder as described herein by administering to the subject a therapeutic agent (e.g., an oligonucleotide or vector or transgene encoding same). In some embodiments, the subject to be treated is a subject who will benefit therapeutically from a reduction in the amount of ALDH2 protein, e.g., in the central nervous system.


Methods described herein typically involve administering to a subject an effective amount of an oligonucleotide, that is, an amount capable of producing a desirable therapeutic result. A therapeutically acceptable amount may be an amount that is capable of treating a disease or disorder. The appropriate dosage for any one subject will depend on certain factors, including the subject's size, body surface area, age, the composition to be administered, the active ingredient(s) in the composition, time and route of administration, general health, and other drugs being administered concurrently.


In some embodiments, a subject is administered any one of the compositions disclosed herein to the cerebrospinal fluid (CSF) of a subject, e.g., by injection or infusion. In some embodiments, oligonucleotides disclosed herein are delivered via intraventricular, intracavitary, intrathecal, or interstitial administration.


In some embodiments, oligonucleotides are administered at a dose in a range of 0.1 mg/kg to 25 mg/kg (e.g., 1 mg/kg to 5 mg/kg). In some embodiments, oligonucleotides are administered at a dose in a range of 0.1 mg/kg to 5 mg/kg or in a range of 0.5 mg/kg to 5 mg/kg.


As a non-limiting set of examples, the oligonucleotides of the instant disclosure would typically be administered once per year, twice per year, quarterly (once every three months), bi-monthly (once every two months), monthly, or weekly.


In some embodiments, the subject to be treated is a human or non-human primate or other mammalian subject. Other exemplary subjects include domesticated animals such as dogs and cats; livestock such as horses, cattle, pigs, sheep, goats, and chickens; and animals such as mice, rats, guinea pigs, and hamsters.


iii. Reducing Target Gene Expression in Cells


In some aspects the present disclosure provides methods of using the oligonucleotide derivatives (e.g., Conjugates A, B, C, D, E, F, or G) for reducing the expression of a target gene in a subject.


In some embodiments, the method comprises administering any of the oligonucleotide derivatives (e.g., Conjugates A, B, C, D, E, F, or G) to the cerebrospinal fluid of the subject. The antisense and sense strand of the oligonucleotide can be engineered to target any target gene. In some embodiments, the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to the target gene.


Other genes that could be targeted with the methods and oligonucleotides described herein include those identified as causing: Spinocerebellar Ataxia Type 1 (Ataxin-1, and/or Ataxin-3); the β-amyloid precursor protein gene (APP or BACE1) or mutants thereof; Dystonia (DYT1); Amyotrophic Lateral Sclerosis “ALS” or Lou Gehrig's Disease (SOD1) and, various genes that lead to tumors in the CNS.


In some embodiments, the gene of interest is selected from the group consisting of ALDH2, Ataxin-1, Ataxin-3, APP, BACE1, DYT1, and SOD1.


EXAMPLES
Example 1: Delivery of GalNAc-Conjugated ALDH2 Oligonucleotide to the Central Nervous System (CNS)

The central nervous system (CNS) is a protected environment. The circulating protein content in the cerebrospinal fluid (CSF) is less than 1% of that in plasma, and the CSF has little intrinsic nuclease activity. The CNS is ‘immune-privileged’ because the blood-brain barrier prevents circulation of immune cells. Oligonucleotides administered into CSF distribute via CSF bulk flow and have extended tissue half-lives (up to 200 days in brain and spinal cord following intracerebroventricular (ICV) infusion). Neural cells readily take up oligonucleotides. The size and/or lipophilicity of RNAi oligonucleotides can be engineered to reduce their elimination from CSF. However, RNAi oligonucleotides do not cross the blood-brain barrier, and thus require direct administration into the CNS (e.g., intrathecal or ICV injection). Oligonucleotides are cleared from CSF via lymphatic system and subject to same considerations/limitations as systemically administered oligonucleotides (e.g., renal toxicity, thrombocytopenia). In one embodiment of the present disclosure, the active guide strands are prepared in larger oligonucleotide carriers that are chemically modified to protect the compound against rapid elimination from the CNS. The chemical modification to the oligonucleotide carrier includes simply larger molecular size, lipophilicity, dimerization, modifications to charge or polarity, increase in molecular weight each in an effort to reduce or slow the ability of the CNS to remove the overall molecule until the guide strand can load into the RISC and inhibit the target mRNA.


In some embodiments, when eliminated from the CNS and located in another bodily compartment the oligonucleotides of the current invention are modified to be easily accessible to nucleases and other degradative molecules such that oligonucleotides outside the CNS are easily degraded. In this way off target effects are limited or prevented.


In this study, GalNAc-conjugated ALDH2 oligonucleotides were delivered to the CNS of female CD-1 mice via direct intraventricular injection (FIG. 1). It was first shown that FastGreem dye injected to the right lateral ventricle injection site distributed throughout the ventricular system (FIG. 2).


GalNAc-conjugated ALDH2 oligonucleotides are effective in reducing ALDH2 expression in the liver but is rapidly cleared from CNS compartment. Two derivatives of the S585-AS595-Conjugate A oligonucleotide (S608-AS595-Conjugate A and S608-AS595-Conjugate A-PS tail) were designed to enhance CSF retention. These oligonucleotides further comprise a combination of 2′-fluoro and 2′-O-methyl modified nucleotides, phophorothioate linkages, and/or include a phosphate analog positioned at the 5′ terminal nucleotide of their antisense strands.


The phosphothioate (PS)-modified nucleotides at the 3′ portion of the antisense strand was predicted to enhance CSF retention and neural cell uptake. A non-PS-modified tail included as control to decouple the contributions of PS modifications or asymmetry in mediating uptake.


To study the activities of the GalNAc-conjugated ALDH2 oligonucleotides (parent and derivatives) in reducing ALDH2 expression in the central nervous system, the GalNAc-conjugated ALDH2 oligonucleotides (parent and derivatives) were administered to mice (n=4 for each group) via direct intraventricular injection (ICV) and the remaining ALDH2 mRNA level in different regions of the mice brain were assessed 5 days post administration. The study design is shown in Table 1.









TABLE 1







CNS activity study design
















Stock solution



Group
Route
*Dose (μg)
Volume (μl)
(mg/ml)
Oligonucleotide





A
ICV
NA
10
10
NA


B
ICV
100
10
10
S585-AS595-







Conjugate A


C
ICV
100
10
10
S608-AS595-







Conjugate A


D
ICV
100
10
10
S608-AS595-







Conjugate A-PS





*100 μg does is equivalent to 4 mg/kg.






The result shows that all tested GalNAc-conjugated ALDH2 oligonucleotides reduced ALDH2 expression in different brain regions and in the liver (FIG. 3). Further, as demonstrated in FIG. 4, one single 100 μg does of GalNAc-conjugated ALDH2 oligonucleotides administered to mice via ICV administration showed similar activities in reducing ALDH2 expression in the cerebellum, compared to a benchmark 900 μg dose (in rat) via intrathecal administration for a different RNAi oligonucleotide (conjugated or unconjugated).


Example 2. Dose Response of GalNAc-Conjugated ALDH2 Oligonucleotides in the CNS

The GalNAc-conjugated ALDH2 oligonucleotide (S585-AS595-Conjugate A) was tested using the same assay as above, but at two different concentrations (250 μg and 500 μg). The GalNAc-conjugated ALDH2 oligonucleotide was administered to mice via ICV and tissues (Striatum, cortex (somatosensory and frontal), hippocampus, hypothalamus, cerebellum, spinal cord) were collected at day 7 or day 28 post administration. The remaining ALDH2 mRNA level in the tissues were assessed using RT-PCT. The amount of the GalNAc-conjugated ALDH2 oligonucleotide in the tissues were assessed using SL-qPCT. The study design is shown in Table 2.









TABLE 2







Dose response study design











Group
Route
*Dose (μg)
Volume (μl)
Stock solution (mg/ml)





A
ICV
NA
10
NA


B
ICV
250
10
25


C
ICV
500
10
50


D
ICV
250
10
25


E
ICV
500
10
50









The results show that the GalNAc-conjugated ALDH2 oligonucleotide (5585-AS595-Conjugate A) significantly reduced ALDH2 mRNA level in all brain and spinal cord regions 7 days post administration (FIG. 5). ED50 is less than 100 μg for all regions. Note in FIG. 7, results for 100 μg dose obtained on day 5 were also included. Sustained silencing of ALDH2 mRNA expression was also observed throughout the brain (FIG. 6) and across the spinal cord (FIG. 7) over 28 days following a single, ICV injection of the GalNAc-conjugated ALDH2 oligonucleotide at 250 μg or 500 μg doses. The ICV injected the GalNAc-conjugated ALDH2 oligonucleotide also reduced ALDH2 expression level in the level 7 and 28 days after administration (FIG. 8).


Example 3. CNS Duration of the Effect of GalNAc-Conjugated ALDH2 Oligonucleotide

The duration of effect of GalNAc-conjugated ALDH2 oligonucleotide (5585-AS595-Conjugate A) in the brain and spinal cord after a single, bolus ICV injection was also assessed. GalNAc-conjugated ALDH2 oligonucleotide were to CD-1 female mice (6-8 weeks of age) delivered via ICV injection to the right lateral ventricle at two dose levels, 250 μg and 500 μg. Mice were sacrificed 7, 28, and 56 days after infusion and tissues (Striatum, cortex (somatosensory and frontal), hippocampus, hypothalamus, spinal cord) were collected. The remaining ALDH2 mRNA level in the tissues were assessed using RT-PCT. The study design is shown in Table 3 below.









TABLE 3







Duration study











Group
Route
*Dose (μg)
Volume (μl)
Stock solution (mg/ml)





A
ICV
NA
10
NA


B
ICV
250
10
25


C
ICV
500
10
50









The results show that the ALDH2 reducing effect of the GalNAc-conjugated ALDH2 oligonucleotide (S585-AS595-Conjugate A) lasted around 30 days in different regions of the brain (FIG. 9) and across the spinal cord (FIG. 10). After 30 days, the remaining ALDH2 mRNA level increased overtime, but did not rise to the mRNA level before knockdown in at the 56-day time point.


The neurotoxicity of the GalNAc-conjugated ALDH2 oligonucleotide (S585-AS595-Conjugate A) was also assessed. No Gfap upregulation was observed following administration of either 250 μg or 500 μg of the GalNAc-conjugated ALDH2 oligonucleotide (FIG. 11). No gliosis (reactive change in glial cells in response to CNS injury) was observed indicating tolerability. Toxicity and therapeutic efficacy of those compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices on this scale are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.


Example 4. ALDH2 RNAi Oligonucleotide Derivatives

To determine whether GalNAc conjugation is required for neuronal delivery and to identify of structural variants of the GalNAc-conjugated ALDH2 oligonucleotide that have ALDH2 inhibiting activity in the CNS, a panel of ALDH2 RNAi oligonucleotide derivatives were designed (Conjugates A-G, FIG. 23). All derivatives form different structures at the 5′ end of the sense strand, with or without a tetraloop structure. Exemplary modified nucleotides in the tetraloop portion of the oligonucleotide derivatives are shown in FIG. 22. Additionally, all further comprise a combination of 2′-fluoro and 2′-O-methyl modified nucleotides, phophorothioate linkages, and/or include a phosphate analog positioned at the 5′ terminal nucleotide of their antisense strands.


Conjugates A, B, D, E, F, and G comprise a tetraloop comprising a sequence set forth as GAAA and comprise a sense strand having a sequence as set forth in SEQ ID NO: 585, and an antisense strand having a sequence as set forth in SEQ ID NO: 595. Conjugate C does not contain a tetraloop and the 3′ of the sense strand and the 5′ end of the anti-sense strand form a blunt end. Conjugate C comprises a sense strand having a sequence as set forth in SEQ ID NO: 609, and an antisense strand having a sequence as set forth in SEQ ID NO: 595.


In Conjugate A, each of the A in GAAA sequence is conjugated to a GalNAc moiety and the G in the GAAA sequence comprises a 2′-O-methyl modification.


In Conjugate B, each of the A in GAAA sequence is conjugated to a GalNAc moiety and the G in the GAAA sequence comprises a 2′-OH.


In Conjugate D, each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification.


In Conjugate E, each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification.


In Conjugate F, each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification.


In Conjugate G, each of the A in the GAAA sequence comprises a 2′-adem and the G in the GAAA sequence comprises a 2′-O-methyl modification.


The activities of the derivatives in reducing ALDH2 expression in the CNS were assessed. A single, bolus ICV injection of the ALDH2 RNAi oligonucleotide derivatives to CD-1 female mice (6-8 weeks of age, n=4). The derivatives were delivered via ICV injection to the right lateral ventricle at 200 μg. Mice were sacrificed 14 days after infusion and tissues (Somatosensory cortex, hippocampus, striatum, frontal cortex, cerebellum, hypothalamus, cervical spinal cord, thoracic spinal cord, lumbar spinal cord, liver) were collected. The remaining ALDH2 mRNA level in the tissues were assessed using RT-PCT. The amount of the ALDH2 RNAi oligonucleotide derivatives in the tissues were assessed using SL-qPCT. The study design is shown in Table 4.









TABLE 4







Activities of ALDH2 RNAi oligonucleotide derivatives
















Stock solution



Group
Route
*Dose (μg)
Volume (μl)
(mg/ml)
Oligonucleotide





A
ICV
NA
10
NA
NA


B
ICV
200
10
20
S585-AS595-







Conjugate A


C
ICV
200
10
20
S585-AS595-







Conjugate B


D
ICV
200
10
20
S609-AS595-







Conjugate C


E
ICV
200
10
20
S585-AS595-







Conjugate D


F
ICV
200
10
20
S585-AS595-







Conjugate E


G
ICV
200
10
20
S585-AS595-







Conjugate F


H
ICV
200
10
20
S585-AS595-







Conjugate G





*Systemic dose equivalency: ~ 8 mg/kg for tetraloop structures, ~13.5 mg/kg for shortened duplex







FIG. 12 shows that the non-GalNAc-conjugated oligonucleotides are inactive in the liver after two weeks. Conjugate B is still partially active in liver, likely due to high dose (8 mg/kg equivalent). FIG. 13 shows that GalNAc conjugation is not required for oligonucleotide efficacy throughout the brain.


All conjugates were effective in reducing ALDH2 mRNA level in the frontal cortex (FIG. 14), striatum (FIG. 15), somatosensory cortex (FIG. 16), hippocampus (FIG. 17), hypothalamus (FIG. 18), cerebellum (FIG. 19), and across the spinal cord (FIG. 21). A summary of relative exposure of the ALDH2 RNAi oligonucleotide derivatives across different brain regions is shown in FIG. 20.


The results indicate that non-GalNAc-conjugated RNAi oligonucleotides are inactive in the liver after two weeks and GalNAc conjugation is not required for neural cell uptake and conjugate efficacy. All derivatives showed roughly comparable distribution across the brain and spinal cord (although there was up to a 10-fold difference in absolute accumulation levels between some groups). Proximal to the site of infusion (somatosensory cortex and hippocampus), enhanced activity (by 20-40%) were observed with non-GalNAc-conjugated constructs (Conjugates C-G). Distal from the site of infusion (frontal cortex, striatum, hypothalamus, cerebellum, spinal cord), comparable activity between GalNAc-conjugated and non-conjugated derivatives were observed.


In general, Conjugate E (2′-OH-substituted tetraloop) is less efficacious. The highest overall exposure was observed with Conjugate G (2′-adem-substituted tetraloop) and Conjugate F (2′-MOE-substituted tetraloop).


Target Sequences in the ALDH2 gene are provided in Table 5.









TABLE 5







Sequences of Hotspots









Hotspot




Position




In Human

SEQ


ALDH2

ID


mRNA
Sequence
NO.





181-273
AACCAGCAGCCCGAGGTCTTCTGCAAC
601



CAGATTTTCATAAACAATGAATGGCAC




GATGCCGTCAGCAGGAAAACATTCCCC




ACCGTCAATCCG






445-539
ACCTACCTGGCGGCCTTGGAGACCCTG
602



GACAATGGCAAGCCCTATGTCATCTCC




TACCTGGTGGATTTGGACATGGTCCTC




AAATGTCTCCGGTATTATGC






646-696
CCGTGGAATTTCCCGCTCCTGATGCAA
603



GCATGGAAGCTGGGCCCAGCCTTG






691-749
GCCTTGGCAACTGGAAACGTGGTTGTG
604



ATGAAGGTAGCTGAGCAGACACCCCTC




ACCGC






1165-1235
GAGCAGGGGCCGCAGGTGGATGAAACT
605



CAGTTTAAGAAGATCCTCGGCTACATC




AACACGGGGAAGCAAGA






1770-1821
TCTCTTGGGTCAAGAAAGTTCTAGAAT
606



TTGAATTGATAAACATGGTGGGTTG






1824-1916
TGAGGGTAAGAGTATATGAGGAACCTT
607



TTAAACGACAACAATACTGCTAGCTTT




CAGGATGATTTTTAAAAAATAGATTCA




AATGTGTTATCC









Description of Oligonucleotide Nomenclature

All oligonucleotides described herein are designated either SN1-ASN2-MN3. The following designations apply:

    • N1: sequence identifier number of the sense strand sequence
    • N2: sequence identifier number of the antisense strand sequence


For example, S27-AS317 represents an oligonucleotide with a sense sequence that is set forth by SEQ ID NO: 27, an antisense sequence that is set forth by SEQ ID NO: 317.


REFERENCES



  • 1. Fire A. and Xu S, “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans,” Nature, 1998, 391(6669):806-811.

  • 2. Hannon, G. J., “RNA interference,” Nature, 2002, 418:244-251.

  • 3. Xia et al., “RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia,” Nat Med., 2004, 10(8):816-820.



The disclosure illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.


In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.


It should be appreciated that, in some embodiments, sequences presented in the sequence listing may be referred to in describing the structure of an oligonucleotide or other nucleic acid. In such embodiments, the actual oligonucleotide or other nucleic acid may have one or more alternative nucleotides (e.g., an RNA counterpart of a DNA nucleotide or a DNA counterpart of an RNA nucleotide) and/or one or more modified nucleotides and/or one or more modified internucleotide linkages and/or one or more other modification compared with the specified sequence while retaining essentially same or similar complementary properties as the specified sequence.


The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.


Embodiments of this invention are described herein. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description.


The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. The contents of all references, patents, and patent applications cited throughout this application are hereby incorporated by reference.













APPENDIX A







S

AS




SEQ

SEQ


App
Sense Sequence/
ID
Antisense
ID


Name
mRNA seq
NO
Sequence
NO







S1-
GAGGUCUUCUGCAACCAG
  1
UGAAAAUCUGGUUGCAGA
291


AS291
AUUUUCA

AGACCUCGG






S2-
AGGUCUUCUGCAACCAGA
  2
AUGAAAAUCUGGUUGCAG
292


AS292
UUUUCAT

AAGACCUCG






S3-
GUCUUCUGCAACCAGAUU
  3
UUAUGAAAAUCUGGUUGC
293


AS293
UUCAUAA

AGAAGACCU






S4-
CUUCUGCAACCAGAUUUU
  4
GUUUAUGAAAAUCUGGUU
294


AS294
CAUAAAC

GCAGAAGAC






S5-
UUCUGCAACCAGAUUUUC
  5
UGUUUAUGAAAAUCUGGU
295


AS295
AUAAACA

UGCAGAAGA






S6-
UCUGCAACCAGAUUUUCA
  6
UUGUUUAUGAAAAUCUGG
296


AS296
UAAACAA

UUGCAGAAG






S7-
CUGCAACCAGAUUUUCAU
  7
AUUGUUUAUGAAAAUCUG
297


AS297
AAACAAT

GUUGCAGAA






S8-
UGCAACCAGAUUUUCAUA
  8
CAUUGUUUAUGAAAAUCU
298


AS298
AACAATG

GGUUGCAGA






S9-
GCAACCAGAUUUUCAUAA
  9
UCAUUGUUUAUGAAAAUC
299


AS299
ACAAUGA

UGGUUGCAG






S10-
CAACCAGAUUUUCAUAAA
 10
UUCAUUGUUUAUGAAAAU
300


AS300
CAAUGAA

CUGGUUGCA






S11-
AACCAGAUUUUCAUAAAC
 11
AUUCAUUGUUUAUGAAAA
301


AS301
AAUGAAT

UCUGGUUGC






S12-
ACCAGAUUUUCAUAAACA
 12
CAUUCAUUGUUUAUGAAA
302


AS302
AUGAATG

AUCUGGUUG






S13-
CCAGAUUUUCAUAAACAA
 13
CCAUUCAUUGUUUAUGAA
303


AS303
UGAAUGG

AAUCUGGUU






S14-
CAGAUUUUCAUAAACAAU
 14
GCCAUUCAUUGUUUAUGA
304


AS304
GAAUGGC

AAAUCUGGU






S17-
AGAUUUUCAUAAACAAUG
 17
UGCCAUUCAUUGUUUAUG
307


AS307
AAUGGCA

AAAAUCUGG






S18-
GAUUUUCAUAAACAAUGA
 18
GUGCCAUUCAUUGUUUAU
308


AS308
AUGGCAC

GAAAAUCUG






S19-
GCCGUCAGCAGGAAAACA
 19
UGGGGAAUGUUUUCCUGC
309


AS309
UUCCCCA

UGACGGCAU






S20-
CCGUCAGCAGGAAAACAU
 20
GUGGGGAAUGUUUUCCUG
310


AS310
UCCCCAC

CUGACGGCA






S21-
GGCCUUGGAGACCCUGGA
 21
GCCAUUGUCCAGGGUCUC
311


AS311
CAAUGGC

CAAGGCCGC






S22-
GCCUUGGAGACCCUGGAC
 22
UGCCAUUGUCCAGGGUCU
312


AS312
AAUGGCA

CCAAGGCCG






S23-
CCUUGGAGACCCUGGACA
 23
UUGCCAUUGUCCAGGGUC
313


AS313
AUGGCAA

UCCAAGGCC






S24-
UACCUGGUGGAUUUGGAC
 24
GGACCAUGUCCAAAUCCA
314


AS314
AUGGUCC

CCAGGUAGG






S25-
ACCUGGUGGAUUUGGACA
 25
AGGACCAUGUCCAAAUCC
315


AS315
UGGUCCT

ACCAGGUAG






S26-
CCUGGUGGAUUUGGACAU
 26
GAGGACCAUGUCCAAAUC
316


AS316
GGUCCTC

CACCAGGUA






S27-
CUGGUGGAUUUGGACAUG
 27
UGAGGACCAUGUCCAAAU
317


AS317
GUCCUCA

CCACCAGGU






S28-
UGGUGGAUUUGGACAUG
 28
UUGAGGACCAUGUCCAAA
318


AS318
GUCCUCAA

UCCACCAGG






S29-
GGUGGAUUUGGACAUGG
 29
UUUGAGGACCAUGUCCAA
319


AS319
UCCUCAAA

AUCCACCAG






S30-
GUGGAUUUGGACAUGGUC
 30
AUUUGAGGACCAUGUCCA
320


AS320
CUCAAAT

AAUCCACCA






S31-
UGGAUUUGGACAUGGUCC
 31
CAUUUGAGGACCAUGUCC
321


AS321
UCAAATG

AAAUCCACC






S32-
GAUUUGGACAUGGUCCUC
 32
GACAUUUGAGGACCAUGU
322


AS322
AAAUGTC

CCAAAUCCA






S33-
UUCCCGCUCCUGAUGCAA
 33
UCCAUGCUUGCAUCAGGA
323


AS323
GCAUGGA

GCGGGAAAU






S34-
UCCCGCUCCUGAUGCAAG
 34
UUCCAUGCUUGCAUCAGG
324


AS324
CAUGGAA

AGCGGGAAA






S35-
CCCGCUCCUGAUGCAAGC
 35
CUUCCAUGCUUGCAUCAG
325


AS325
AUGGAAG

GAGCGGGAA






S36-
CCGCUCCUGAUGCAAGCA
 36
GCUUCCAUGCUUGCAUCA
326


AS326
UGGAAGC

GGAGCGGGA






S37-
CGCUCCUGAUGCAAGCAU
 37
AGCUUCCAUGCUUGCAUC
327


AS327
GGAAGCT

AGGAGCGGG






S38-
GCUCCUGAUGCAAGCAUG
 38
CAGCUUCCAUGCUUGCAU
328


AS328
GAAGCTG

CAGGAGCGG






S39-
CUCCUGAUGCAAGCAUGG
 39
CCAGCUUCCAUGCUUGCA
329


AS329
AAGCUGG

UCAGGAGCG






S40-
UCCUGAUGCAAGCAUGGA
 40
CCCAGCUUCCAUGCUUGC
330


AS330
AGCUGGG

AUCAGGAGC






S41-
AACUGGAAACGUGGUUGU
 41
CUUCAUCACAACCACGUU
331


AS331
GAUGAAG

UCCAGUUGC






S42-
ACUGGAAACGUGGUUGUG
 42
CCUUCAUCACAACCACGU
332


AS332
AUGAAGG

UUCCAGUUG






S43-
CUGGAAACGUGGUUGUGA
 43
ACCUUCAUCACAACCACG
333


AS333
UGAAGGT

UUUCCAGUU






S44-
UGGAAACGUGGUUGUGA
 44
UACCUUCAUCACAACCAC
334


AS334
UGAAGGTA

GUUUCCAGU






S45-
GGAAACGUGGUUGUGAU
 45
CUACCUUCAUCACAACCA
335


AS335
GAAGGUAG

CGUUUCCAG






S46-
GAAACGUGGUUGUGAUG
 46
GCUACCUUCAUCACAACC
336


AS336
AAGGUAGC

ACGUUUCCA






S47-
AACGUGGUUGUGAUGAA
 47
CAGCUACCUUCAUCACAA
337


AS337
GGUAGCTG

CCACGUUUC






S48-
ACGUGGUUGUGAUGAAG
 48
UCAGCUACCUUCAUCACA
338


AS338
GUAGCUGA

ACCACGUUU






S49-
CGUGGUUGUGAUGAAGG
 49
CUCAGCUACCUUCAUCAC
339


AS339
UAGCUGAG

AACCACGUU






S50-
GUUGUGAUGAAGGUAGC
 50
UCUGCUCAGCUACCUUCA
340


AS340
UGAGCAGA

UCACAACCA






S51-
GUGAUGAAGGUAGCUGA
 51
GUGUCUGCUCAGCUACCU
341


AS341
GCAGACAC

UCAUCACAA






S52-
AGGAUGUGGACAAAGUG
 52
GUGAAUGCCACUUUGUCC
342


AS342
GCAUUCAC

ACAUCCUCA






S53-
GGGAGCAGCAACCUCAAG
 53
UCACUCUCUUGAGGUUGC
343


AS343
AGAGUGA

UGCUCCCAG






S54-
GGAGCAGCAACCUCAAGA
 54
GUCACUCUCUUGAGGUUG
344


AS344
GAGUGAC

CUGCUCCCA






S55-
GAGCAGCAACCUCAAGAG
 55
GGUCACUCUCUUGAGGUU
345


AS345
AGUGACC

GCUGCUCCC






S56-
AGCAGCAACCUCAAGAGA
 56
AGGUCACUCUCUUGAGGU
346


AS346
GUGACCT

UGCUGCUCC






S57-
GCAGCAACCUCAAGAGAG
 57
AAGGUCACUCUCUUGAGG
347


AS347
UGACCTT

UUGCUGCUC






S58-
GCCCUGUUCUUCAACCAG
 58
ACUGGCCCUGGUUGAAGA
348


AS348
GGCCAGT

ACAGGGCGA






S59-
CCCUGUUCUUCAACCAGG
 59
CACUGGCCCUGGUUGAAG
349


AS349
GCCAGTG

AACAGGGCG






S60-
CCUGUUCUUCAACCAGGG
 60
GCACUGGCCCUGGUUGAA
350


AS350
CCAGUGC

GAACAGGGC






S61-
CUGUUCUUCAACCAGGGC
 61
AGCACUGGCCCUGGUUGA
351


AS351
CAGUGCT

AGAACAGGG






S62-
UGUUCUUCAACCAGGGCC
 62
CAGCACUGGCCCUGGUUG
352


AS352
AGUGCTG

AAGAACAGG






S63-
GUUCUUCAACCAGGGCCA
 63
GCAGCACUGGCCCUGGUU
353


AS353
GUGCUGC

GAAGAACAG






S64-
UUCUUCAACCAGGGCCAG
 64
AGCAGCACUGGCCCUGGU
354


AS354
UGCUGCT

UGAAGAACA






S65-
CUUCAACCAGGGCCAGUG
 65
ACAGCAGCACUGGCCCUG
355


AS355
CUGCUGT

GUUGAAGAA






S66-
UUCAACCAGGGCCAGUGC
 66
CACAGCAGCACUGGCCCU
356


AS356
UGCUGTG

GGUUGAAGA






S67-
CAACCAGGGCCAGUGCUG
 67
GGCACAGCAGCACUGGCC
357


AS357
CUGUGCC

CUGGUUGAA






S68-
GGCUCCCGGACCUUCGUG
 68
CCUCCUGCACGAAGGUCC
358


AS358
CAGGAGG

GGGAGCCGG






S69-
GCUCCCGGACCUUCGUGC
 69
UCCUCCUGCACGAAGGUC
359


AS359
AGGAGGA

CGGGAGCCG






S70-
CUCCCGGACCUUCGUGCA
 70
GUCCUCCUGCACGAAGGU
360


AS360
GGAGGAC

CCGGGAGCC






S71-
UCCCGGACCUUCGUGCAG
 71
UGUCCUCCUGCACGAAGG
361


AS361
GAGGACA

UCCGGGAGC






S72-
CCCGGACCUUCGUGCAGG
 72
AUGUCCUCCUGCACGAAG
362


AS362
AGGACAT

GUCCGGGAG






S73-
CCGGACCUUCGUGCAGGA
 73
GAUGUCCUCCUGCACGAA
363


AS363
GGACATC

GGUCCGGGA






S74-
GGAGGACAUCUAUGAUGA
 74
CACAAACUCAUCAUAGAU
364


AS364
GUUUGTG

GUCCUCCUG






S75-
CGGGCCAAGUCUCGGGUG
 75
UCCCGACCACCCGAGACU
365


AS365
GUCGGGA

UGGCCCGGG






S76-
GGGCCAAGUCUCGGGUGG
 76
UUCCCGACCACCCGAGAC
366


AS366
UCGGGAA

UUGGCCCGG






S77-
GCAGGUGGAUGAAACUCA
 77
CUUAAACUGAGUUUCAUC
367


AS367
GUUUAAG

CACCUGCGG






S78-
CAGGUGGAUGAAACUCAG
 78
UCUUAAACUGAGUUUCAU
368


AS368
UUUAAGA

CCACCUGCG






S79-
AGGUGGAUGAAACUCAGU
 79
UUCUUAAACUGAGUUUCA
369


AS369
UUAAGAA

UCCACCUGC






S80-
GGUGGAUGAAACUCAGUU
 80
CUUCUUAAACUGAGUUUC
370


AS370
UAAGAAG

AUCCACCUG






S81-
GUGGAUGAAACUCAGUUU
 81
UCUUCUUAAACUGAGUUU
371


AS371
AAGAAGA

CAUCCACCU






S82-
UGGAUGAAACUCAGUUUA
 82
AUCUUCUUAAACUGAGUU
372


AS372
AGAAGAT

UCAUCCACC






S83-
GGAUGAAACUCAGUUUAA
 83
GAUCUUCUUAAACUGAGU
373


AS373
GAAGATC

UUCAUCCAC






S84-
GAUGAAACUCAGUUUAAG
 84
GGAUCUUCUUAAACUGAG
374


AS374
AAGAUCC

UUUCAUCCA






S85-
AUGAAACUCAGUUUAAGA
 85
AGGAUCUUCUUAAACUGA
375


AS375
AGAUCCT

GUUUCAUCC






S86-
UGAAACUCAGUUUAAGAA
 86
GAGGAUCUUCUUAAACUG
376


AS376
GAUCCTC

AGUUUCAUC






S87-
GAAACUCAGUUUAAGAAG
 87
CGAGGAUCUUCUUAAACU
377


AS377
AUCCUCG

GAGUUUCAU






S88-
AAACUCAGUUUAAGAAGA
 88
CCGAGGAUCUUCUUAAAC
378


AS378
UCCUCGG

UGAGUUUCA






S89-
AACUCAGUUUAAGAAGAU
 89
GCCGAGGAUCUUCUUAAA
379


AS379
CCUCGGC

CUGAGUUUC






S90-
ACUCAGUUUAAGAAGAUC
 90
AGCCGAGGAUCUUCUUAA
380


AS380
CUCGGCT

ACUGAGUUU






S91-
CUCAGUUUAAGAAGAUCC
 91
UAGCCGAGGAUCUUCUUA
381


AS381
UCGGCTA

AACUGAGUU






S92-
UCAGUUUAAGAAGAUCCU
 92
GUAGCCGAGGAUCUUCUU
382


AS382
CGGCUAC

AAACUGAGU






S93-
CAGUUUAAGAAGAUCCUC
 93
UGUAGCCGAGGAUCUUCU
383


AS383
GGCUACA

UAAACUGAG






S94-
AGUUUAAGAAGAUCCUCG
 94
AUGUAGCCGAGGAUCUUC
384


AS384
GCUACAT

UUAAACUGA






S95-
GUUUAAGAAGAUCCUCGG
 95
GAUGUAGCCGAGGAUCUU
385


AS385
CUACATC

CUUAAACUG






S96-
UUUAAGAAGAUCCUCGGC
 96
UGAUGUAGCCGAGGAUCU
386


AS386
UACAUCA

UCUUAAACU






S97-
UUAAGAAGAUCCUCGGCU
 97
UUGAUGUAGCCGAGGAUC
387


AS387
ACAUCAA

UUCUUAAAC






S98-
UAAGAAGAUCCUCGGCUA
 98
GUUGAUGUAGCCGAGGAU
388


AS388
CAUCAAC

CUUCUUAAA






S99-
AAGAAGAUCCUCGGCUAC
 99
UGUUGAUGUAGCCGAGGA
389


AS389
AUCAACA

UCUUCUUAA






S100-
AGAAGAUCCUCGGCUACA
100
GUGUUGAUGUAGCCGAGG
390


AS390
UCAACAC

AUCUUCUUA






S101-
GAAGAUCCUCGGCUACAU
101
CGUGUUGAUGUAGCCGAG
391


AS391
CAACACG

GAUCUUCUU






S102-
AAGAUCCUCGGCUACAUC
102
CCGUGUUGAUGUAGCCGA
392


AS392
AACACGG

GGAUCUUCU






S103-
AGAUCCUCGGCUACAUCA
103
CCCGUGUUGAUGUAGCCG
393


AS393
ACACGGG

AGGAUCUUC






S104-
UGCUGCUGACCGUGGUUA
104
GAUGAAGUAACCACGGUC
394


AS394
CUUCATC

AGCAGCAAU






S105-
GCUGCUGACCGUGGUUAC
105
GGAUGAAGUAACCACGGU
395


AS395
UUCAUCC

CAGCAGCAA






S106-
CUGCUGACCGUGGUUACU
106
UGGAUGAAGUAACCACGG
396


AS396
UCAUCCA

UCAGCAGCA






S107-
GCUGACCGUGGUUACUUC
107
GCUGGAUGAAGUAACCAC
397


AS397
AUCCAGC

GGUCAGCAG






S108-
CCAGUGAUGCAGAUCCUG
108
UGAACUUCAGGAUCUGCA
398


AS398
AAGUUCA

UCACUGGCC






S109-
AGUGAUGCAGAUCCUGAA
109
CUUGAACUUCAGGAUCUG
399


AS399
GUUCAAG

CAUCACUGG






S110-
GUGAUGCAGAUCCUGAAG
110
UCUUGAACUUCAGGAUCU
400


AS400
UUCAAGA

GCAUCACUG






S111-
UGAUGCAGAUCCUGAAGU
111
GUCUUGAACUUCAGGAUC
401


AS401
UCAAGAC

UGCAUCACU






S112-
GAUGCAGAUCCUGAAGUU
112
GGUCUUGAACUUCAGGAU
402


AS402
CAAGACC

CUGCAUCAC






S113-
AUGCAGAUCCUGAAGUUC
113
UGGUCUUGAACUUCAGGA
403


AS403
AAGACCA

UCUGCAUCA






S114-
GCAGAUCCUGAAGUUCAA
114
UAUGGUCUUGAACUUCAG
404


AS404
GACCATA

GAUCUGCAU






S115-
CAGAUCCUGAAGUUCAAG
115
CUAUGGUCUUGAACUUCA
405


AS405
ACCAUAG

GGAUCUGCA






S116-
AGAUCCUGAAGUUCAAGA
116
UCUAUGGUCUUGAACUUC
406


AS406
CCAUAGA

AGGAUCUGC






S117-
GAUCCUGAAGUUCAAGAC
117
CUCUAUGGUCUUGAACUU
407


AS407
CAUAGAG

CAGGAUCUG






S118-
UCCUGAAGUUCAAGACCA
118
UCCUCUAUGGUCUUGAAC
408


AS408
UAGAGGA

UUCAGGAUC






S119-
AAGUUCAAGACCAUAGAG
119
CAACCUCCUCUAUGGUCU
409


AS409
GAGGUTG

UGAACUUCA






S120-
GCUGUCUUCACAAAGGAU
120
UGUCCAAAUCCUUUGUGA
410


AS410
UUGGACA

AGACAGCUG






S121-
GUCUUCACAAAGGAUUUG
121
CCUUGUCCAAAUCCUUUG
411


AS411
GACAAGG

UGAAGACAG






S122-
GCAGGCAUACACUGAAGU
122
AGUUUUCACUUCAGUGUA
412


AS412
GAAAACT

UGCCUGCAG






S123-
CAGGCAUACACUGAAGUG
123
CAGUUUUCACUUCAGUGU
413


AS413
AAAACTG

AUGCCUGCA






S124-
AGGCAUACACUGAAGUGA
124
ACAGUUUUCACUUCAGUG
414


AS414
AAACUGT

UAUGCCUGC






S125-
GGCAUACACUGAAGUGAA
125
GACAGUUUUCACUUCAGU
415


AS415
AACUGTC

GUAUGCCUG






S126-
GCAUACACUGAAGUGAAA
126
UGACAGUUUUCACUUCAG
416


AS416
ACUGUCA

UGUAUGCCU






S127-
AUACACUGAAGUGAAAAC
127
UGUGACAGUUUUCACUUC
417


AS417
UGUCACA

AGUGUAUGC






S128-
UACACUGAAGUGAAAACU
128
CUGUGACAGUUUUCACUU
418


AS418
GUCACAG

CAGUGUAUG






S129-
CUGAAGUGAAAACUGUCA
129
UUGACUGUGACAGUUUUC
419


AS419
CAGUCAA

ACUUCAGUG






S130-
GUCAAAGUGCCUCAGAAG
130
AUGAGUUCUUCUGAGGCA
420


AS420
AACUCAT

CUUUGACUG






S131-
CAAAGUGCCUCAGAAGAA
131
UUAUGAGUUCUUCUGAGG
421


AS421
CUCAUAA

CACUUUGAC






S132-
AAGUGCCUCAGAAGAACU
132
UCUUAUGAGUUCUUCUGA
422


AS422
CAUAAGA

GGCACUUUG






S133-
AGUGCCUCAGAAGAACUC
133
UUCUUAUGAGUUCUUCUG
423


AS423
AUAAGAA

AGGCACUUU






S134-
GUGCCUCAGAAGAACUCA
134
AUUCUUAUGAGUUCUUCU
424


AS424
UAAGAAT

GAGGCACUU






S135-
UGCCUCAGAAGAACUCAU
135
GAUUCUUAUGAGUUCUUC
425


AS425
AAGAATC

UGAGGCACU






S136-
CCUCAGAAGAACUCAUAA
136
AUGAUUCUUAUGAGUUCU
426


AS426
GAAUCAT

UCUGAGGCA






S137-
CUCAGAAGAACUCAUAAG
137
CAUGAUUCUUAUGAGUUC
427


AS427
AAUCATG

UUCUGAGGC






S138-
UCAGAAGAACUCAUAAGA
138
GCAUGAUUCUUAUGAGUU
428


AS428
AUCAUGC

CUUCUGAGG






S139-
CAGAAGAACUCAUAAGAA
139
UGCAUGAUUCUUAUGAGU
429


AS429
UCAUGCA

UCUUCUGAG






S140-
AGAAGAACUCAUAAGAAU
140
UUGCAUGAUUCUUAUGAG
430


AS430
CAUGCAA

UUCUUCUGA






S141-
GAAGAACUCAUAAGAAUC
141
CUUGCAUGAUUCUUAUGA
431


AS431
AUGCAAG

GUUCUUCUG






S142-
AAGAACUCAUAAGAAUCA
142
GCUUGCAUGAUUCUUAUG
432


AS432
UGCAAGC

AGUUCUUCU






S143-
GAACUCAUAAGAAUCAUG
143
AAGCUUGCAUGAUUCUUA
433


AS433
CAAGCTT

UGAGUUCUU






S144-
AACUCAUAAGAAUCAUGC
144
GAAGCUUGCAUGAUUCUU
434


AS434
AAGCUTC

AUGAGUUCU






S145-
CCCUCAGCCAUUGAUGGA
145
UGAACUUUCCAUCAAUGG
435


AS435
AAGUUCA

CUGAGGGAG






S146-
CCUCAGCCAUUGAUGGAA
146
CUGAACUUUCCAUCAAUG
436


AS436
AGUUCAG

GCUGAGGGA






S147-
UCAGCCAUUGAUGGAAAG
147
UGCUGAACUUUCCAUCAA
437


AS437
UUCAGCA

UGGCUGAGG






S148-
CAGCCAUUGAUGGAAAGU
148
UUGCUGAACUUUCCAUCA
438


AS438
UCAGCAA

AUGGCUGAG






S149-
AGCCAUUGAUGGAAAGUU
149
CUUGCUGAACUUUCCAUC
439


AS439
CAGCAAG

AAUGGCUGA






S150-
GCCAUUGAUGGAAAGUUC
150
UCUUGCUGAACUUUCCAU
440


AS440
AGCAAGA

CAAUGGCUG






S151-
CCAUUGAUGGAAAGUUCA
151
AUCUUGCUGAACUUUCCA
441


AS441
GCAAGAT

UCAAUGGCU






S152-
CAUUGAUGGAAAGUUCAG
152
GAUCUUGCUGAACUUUCC
442


AS442
CAAGATC

AUCAAUGGC






S153-
AUUGAUGGAAAGUUCAGC
153
UGAUCUUGCUGAACUUUC
443


AS443
AAGAUCA

CAUCAAUGG






S154-
UUGAUGGAAAGUUCAGCA
154
CUGAUCUUGCUGAACUUU
444


AS444
AGAUCAG

CCAUCAAUG






S155-
UGAUGGAAAGUUCAGCAA
155
GCUGAUCUUGCUGAACUU
445


AS445
GAUCAGC

UCCAUCAAU






S156-
GAUGGAAAGUUCAGCAAG
156
UGCUGAUCUUGCUGAACU
446


AS446
AUCAGCA

UUCCAUCAA






S157-
AUGGAAAGUUCAGCAAGA
157
UUGCUGAUCUUGCUGAAC
447


AS447
UCAGCAA

UUUCCAUCA






S158-
UGGAAAGUUCAGCAAGAU
158
GUUGCUGAUCUUGCUGAA
448


AS448
CAGCAAC

CUUUCCAUC






S159-
GGAAAGUUCAGCAAGAUC
159
UGUUGCUGAUCUUGCUGA
449


AS449
AGCAACA

ACUUUCCAU






S160-
GAAAGUUCAGCAAGAUCA
160
UUGUUGCUGAUCUUGCUG
450


AS450
GCAACAA

AACUUUCCA






S161-
AAAGUUCAGCAAGAUCAG
161
UUUGUUGCUGAUCUUGCU
451


AS451
CAACAAA

GAACUUUCC






S162-
AAGUUCAGCAAGAUCAGC
162
UUUUGUUGCUGAUCUUGC
452


AS452
AACAAAA

UGAACUUUC






S163-
AUCAGCAACAAAACCAAG
163
CAUUUUUCUUGGUUUUGU
453


AS453
AAAAATG

UGCUGAUCU






S164-
CAGCAACAAAACCAAGAA
164
AUCAUUUUUCUUGGUUUU
454


AS454
AAAUGAT

GUUGCUGAU






S165-
AGCAACAAAACCAAGAAA
165
GAUCAUUUUUCUUGGUUU
455


AS455
AAUGATC

UGUUGCUGA






S166-
ACAAAACCAAGAAAAAUG
166
CAAGGAUCAUUUUUCUUG
456


AS456
AUCCUTG

GUUUUGUUG






S167-
CAAAACCAAGAAAAAUGA
167
GCAAGGAUCAUUUUUCUU
457


AS457
UCCUUGC

GGUUUUGUU






S168-
AGAAAAAUGAUCCUUGCG
168
UUCAGCACGCAAGGAUCA
458


AS458
UGCUGAA

UUUUUCUUG






S169-
AAAAAUGAUCCUUGCGUG
169
UAUUCAGCACGCAAGGAU
459


AS459
CUGAATA

CAUUUUUCU






S170-
AAAAUGAUCCUUGCGUGC
170
AUAUUCAGCACGCAAGGA
460


AS460
UGAAUAT

UCAUUUUUC






S171-
AAAUGAUCCUUGCGUGCU
171
GAUAUUCAGCACGCAAGG
461


AS461
GAAUATC

AUCAUUUUU






S172-
AAUGAUCCUUGCGUGCUG
172
AGAUAUUCAGCACGCAAG
462


AS462
AAUAUCT

GAUCAUUUU






S173-
AUGAUCCUUGCGUGCUGA
173
CAGAUAUUCAGCACGCAA
463


AS463
AUAUCTG

GGAUCAUUU






S174-
UGAUCCUUGCGUGCUGAA
174
UCAGAUAUUCAGCACGCA
464


AS464
UAUCUGA

AGGAUCAUU






S175-
GAUCCUUGCGUGCUGAAU
175
UUCAGAUAUUCAGCACGC
465


AS465
AUCUGAA

AAGGAUCAU






S176-
UCCUUGCGUGCUGAAUAU
176
UUUUCAGAUAUUCAGCAC
466


AS466
CUGAAAA

GCAAGGAUC






S177-
CCUUGCGUGCUGAAUAUC
177
CUUUUCAGAUAUUCAGCA
467


AS467
UGAAAAG

CGCAAGGAU






S178-
CUUGCGUGCUGAAUAUCU
178
UCUUUUCAGAUAUUCAGC
468


AS468
GAAAAGA

ACGCAAGGA






S179-
UUGCGUGCUGAAUAUCUG
179
CUCUUUUCAGAUAUUCAG
469


AS469
AAAAGAG

CACGCAAGG






S180-
UGCGUGCUGAAUAUCUGA
180
UCUCUUUUCAGAUAUUCA
470


AS470
AAAGAGA

GCACGCAAG






S181-
GCGUGCUGAAUAUCUGAA
181
UUCUCUUUUCAGAUAUUC
471


AS471
AAGAGAA

AGCACGCAA






S182-
CGUGCUGAAUAUCUGAAA
182
UUUCUCUUUUCAGAUAUU
472


AS472
AGAGAAA

CAGCACGCA






S183-
GUGCUGAAUAUCUGAAAA
183
AUUUCUCUUUUCAGAUAU
473


AS473
GAGAAAT

UCAGCACGC






S184-
UGCUGAAUAUCUGAAAAG
184
AAUUUCUCUUUUCAGAUA
474


AS474
AGAAATT

UUCAGCACG






S185-
GCUGAAUAUCUGAAAAGA
185
AAAUUUCUCUUUUCAGAU
475


AS475
GAAAUTT

AUUCAGCAC






S186-
CUGAAUAUCUGAAAAGAG
186
AAAAUUUCUCUUUUCAGA
476


AS476
AAAUUTT

UAUUCAGCA






S187-
UGAAUAUCUGAAAAGAG
187
AAAAAUUUCUCUUUUCAG
477


AS477
AAAUUUTT

AUAUUCAGC






S188-
GAAUAUCUGAAAAGAGA
188
GAAAAAUUUCUCUUUUCA
478


AS478
AAUUUUTC

GAUAUUCAG






S189-
AAUAUCUGAAAAGAGAA
189
GGAAAAAUUUCUCUUUUC
479


AS479
AUUUUUCC

AGAUAUUCA






S190-
AUAUCUGAAAAGAGAAA
190
AGGAAAAAUUUCUCUUUU
480


AS480
UUUUUCCT

CAGAUAUUC






S191-
AUCUGAAAAGAGAAAUU
191
GUAGGAAAAAUUUCUCUU
481


AS481
UUUCCUAC

UUCAGAUAU






S192-
GAAAAGAGAAAUUUUUCC
192
UUUUGUAGGAAAAAUUUC
482


AS482
UACAAAA

UCUUUUCAG






S193-
AAAAGAGAAAUUUUUCCU
193
AUUUUGUAGGAAAAAUUU
483


AS483
ACAAAAT

CUCUUUUCA






S194-
AGAGAAAUUUUUCCUACA
194
GAGAUUUUGUAGGAAAAA
484


AS484
AAAUCTC

UUUCUCUUU






S195-
GAGAAAUUUUUCCUACAA
195
AGAGAUUUUGUAGGAAAA
485


AS485
AAUCUCT

AUUUCUCUU






S196-
AGAAAUUUUUCCUACAAA
196
AAGAGAUUUUGUAGGAAA
486


AS486
AUCUCTT

AAUUUCUCU






S197-
CUUGGGUCAAGAAAGUUC
197
AAUUCUAGAACUUUCUUG
487


AS487
UAGAATT

ACCCAAGAG






S198-
GGGUCAAGAAAGUUCUAG
198
UCAAAUUCUAGAACUUUC
488


AS488
AAUUUGA

UUGACCCAA






S199-
GGUCAAGAAAGUUCUAGA
199
UUCAAAUUCUAGAACUUU
489


AS489
AUUUGAA

CUUGACCCA






S200-
GUCAAGAAAGUUCUAGAA
200
AUUCAAAUUCUAGAACUU
490


AS490
UUUGAAT

UCUUGACCC






S201-
UCAAGAAAGUUCUAGAAU
201
AAUUCAAAUUCUAGAACU
491


AS491
UUGAATT

UUCUUGACC






S202-
CAAGAAAGUUCUAGAAUU
202
CAAUUCAAAUUCUAGAAC
492


AS492
UGAAUTG

UUUCUUGAC






S203-
AAGAAAGUUCUAGAAUU
203
UCAAUUCAAAUUCUAGAA
493


AS493
UGAAUUGA

CUUUCUUGA






S204-
AGAAAGUUCUAGAAUUU
204
AUCAAUUCAAAUUCUAGA
494


AS494
GAAUUGAT

ACUUUCUUG






S205-
GAAAGUUCUAGAAUUUG
205
UAUCAAUUCAAAUUCUAG
495


AS495
AAUUGATA

AACUUUCUU






S206-
AAAGUUCUAGAAUUUGA
206
UUAUCAAUUCAAAUUCUA
496


AS496
AUUGAUAA

GAACUUUCU






S207-
AAGUUCUAGAAUUUGAA
207
UUUAUCAAUUCAAAUUCU
497


AS497
UUGAUAAA

AGAACUUUC






S208-
AGUUCUAGAAUUUGAAU
208
GUUUAUCAAUUCAAAUUC
498


AS498
UGAUAAAC

UAGAACUUU






S209-
GUUCUAGAAUUUGAAUU
209
UGUUUAUCAAUUCAAAUU
499


AS499
GAUAAACA

CUAGAACUU






S210-
UUCUAGAAUUUGAAUUG
210
AUGUUUAUCAAUUCAAAU
500


AS500
AUAAACAT

UCUAGAACU






S211-
UCUAGAAUUUGAAUUGA
211
CAUGUUUAUCAAUUCAAA
501


AS501
UAAACATG

UUCUAGAAC






S212-
CUAGAAUUUGAAUUGAU
212
CCAUGUUUAUCAAUUCAA
502


AS502
AAACAUGG

AUUCUAGAA






S213-
UAGAAUUUGAAUUGAUA
213
ACCAUGUUUAUCAAUUCA
503


AS503
AACAUGGT

AAUUCUAGA






S214-
AGAAUUUGAAUUGAUAA
214
CACCAUGUUUAUCAAUUC
504


AS504
ACAUGGTG

AAAUUCUAG






S215-
GAAUUUGAAUUGAUAAA
215
CCACCAUGUUUAUCAAUU
505


AS505
CAUGGUGG

CAAAUUCUA






S216-
UAAGAGUAUAUGAGGAA
216
UUAAAAGGUUCCUCAUAU
506


AS506
CCUUUUAA

ACUCUUACC






S217-
AAGAGUAUAUGAGGAACC
217
UUUAAAAGGUUCCUCAUA
507


AS507
UUUUAAA

UACUCUUAC






S218-
AGAGUAUAUGAGGAACCU
218
GUUUAAAAGGUUCCUCAU
508


AS508
UUUAAAC

AUACUCUUA






S219-
GAGUAUAUGAGGAACCUU
219
CGUUUAAAAGGUUCCUCA
509


AS509
UUAAACG

UAUACUCUU






S220-
AGUAUAUGAGGAACCUUU
220
UCGUUUAAAAGGUUCCUC
510


AS510
UAAACGA

AUAUACUCU






S221-
GUAUAUGAGGAACCUUUU
221
GUCGUUUAAAAGGUUCCU
511


AS511
AAACGAC

CAUAUACUC






S222-
UAUAUGAGGAACCUUUUA
222
UGUCGUUUAAAAGGUUCC
512


AS512
AACGACA

UCAUAUACU






S223-
AUGAGGAACCUUUUAAAC
223
UGUUGUCGUUUAAAAGGU
513


AS513
GACAACA

UCCUCAUAU






S224-
GAGGAACCUUUUAAACGA
224
AUUGUUGUCGUUUAAAAG
514


AS514
CAACAAT

GUUCCUCAU






S225-
AGGAACCUUUUAAACGAC
225
UAUUGUUGUCGUUUAAAA
515


AS515
AACAATA

GGUUCCUCA






S226-
GAACCUUUUAAACGACAA
226
AGUAUUGUUGUCGUUUAA
516


AS516
CAAUACT

AAGGUUCCU






S227-
AACCUUUUAAACGACAAC
227
CAGUAUUGUUGUCGUUUA
517


AS517
AAUACTG

AAAGGUUCC






S228-
ACCUUUUAAACGACAACA
228
GCAGUAUUGUUGUCGUUU
518


AS518
AUACUGC

AAAAGGUUC






S229-
CCUUUUAAACGACAACAA
229
AGCAGUAUUGUUGUCGUU
519


AS519
UACUGCT

UAAAAGGUU






S230-
CUUUUAAACGACAACAAU
230
UAGCAGUAUUGUUGUCGU
520


AS520
ACUGCTA

UUAAAAGGU






S231-
UAAACGACAACAAUACUG
231
AAGCUAGCAGUAUUGUUG
521


AS521
CUAGCTT

UCGUUUAAA






S232-
AAACGACAACAAUACUGC
232
AAAGCUAGCAGUAUUGUU
522


AS522
UAGCUTT

GUCGUUUAA






S233-
AACGACAACAAUACUGCU
233
GAAAGCUAGCAGUAUUGU
523


AS523
AGCUUTC

UGUCGUUUA






S234-
CGACAACAAUACUGCUAG
234
CUGAAAGCUAGCAGUAUU
524


AS524
CUUUCAG

GUUGUCGUU






S235-
GACAACAAUACUGCUAGC
235
CCUGAAAGCUAGCAGUAU
525


AS525
UUUCAGG

UGUUGUCGU






S236-
ACAACAAUACUGCUAGCU
236
UCCUGAAAGCUAGCAGUA
526


AS526
UUCAGGA

UUGUUGUCG






S237-
CAACAAUACUGCUAGCUU
237
AUCCUGAAAGCUAGCAGU
527


AS527
UCAGGAT

AUUGUUGUC






S238-
AACAAUACUGCUAGCUUU
238
CAUCCUGAAAGCUAGCAG
528


AS528
CAGGATG

UAUUGUUGU






S239-
ACAAUACUGCUAGCUUUC
239
UCAUCCUGAAAGCUAGCA
529


AS529
AGGAUGA

GUAUUGUUG






S240-
CAAUACUGCUAGCUUUCA
240
AUCAUCCUGAAAGCUAGC
530


AS530
GGAUGAT

AGUAUUGUU






S241-
AAUACUGCUAGCUUUCAG
241
AAUCAUCCUGAAAGCUAG
531


AS531
GAUGATT

CAGUAUUGU






S242-
AUACUGCUAGCUUUCAGG
242
AAAUCAUCCUGAAAGCUA
532


AS532
AUGAUTT

GCAGUAUUG






S243-
UACUGCUAGCUUUCAGGA
243
AAAAUCAUCCUGAAAGCU
533


AS533
UGAUUTT

AGCAGUAUU






S244-
ACUGCUAGCUUUCAGGAU
244
AAAAAUCAUCCUGAAAGC
534


AS534
GAUUUTT

UAGCAGUAU






S245-
CUGCUAGCUUUCAGGAUG
245
UAAAAAUCAUCCUGAAAG
535


AS535
AUUUUTA

CUAGCAGUA






S246-
UGCUAGCUUUCAGGAUGA
246
UUAAAAAUCAUCCUGAAA
536


AS536
UUUUUAA

GCUAGCAGU






S247-
GCUAGCUUUCAGGAUGAU
247
UUUAAAAAUCAUCCUGAA
537


AS537
UUUUAAA

AGCUAGCAG






S248-
CUAGCUUUCAGGAUGAUU
248
UUUUAAAAAUCAUCCUGA
538


AS538
UUUAAAA

AAGCUAGCA






S249-
AGCUUUCAGGAUGAUUUU
249
UUUUUUAAAAAUCAUCCU
539


AS539
UAAAAAA

GAAAGCUAG






S250-
GCUUUCAGGAUGAUUUUU
250
AUUUUUUAAAAAUCAUCC
540


AS540
AAAAAAT

UGAAAGCUA






S251-
CUUUCAGGAUGAUUUUUA
251
UAUUUUUUAAAAAUCAUC
541


AS541
AAAAATA

CUGAAAGCU






S252-
UUUCAGGAUGAUUUUUA
252
CUAUUUUUUAAAAAUCAU
542


AS542
AAAAAUAG

CCUGAAAGC






S253-
UUCAGGAUGAUUUUUAA
253
UCUAUUUUUUAAAAAUCA
543


AS543
AAAAUAGA

UCCUGAAAG






S254-
UCAGGAUGAUUUUUAAA
254
AUCUAUUUUUUAAAAAUC
544


AS544
AAAUAGAT

AUCCUGAAA






S255-
CAGGAUGAUUUUUAAAA
255
AAUCUAUUUUUUAAAAAU
545


AS545
AAUAGATT

CAUCCUGAA






S256-
AGGAUGAUUUUUAAAAA
256
GAAUCUAUUUUUUAAAAA
546


AS546
AUAGAUTC

UCAUCCUGA






S257-
GGAUGAUUUUUAAAAAA
257
UGAAUCUAUUUUUUAAAA
547


AS547
UAGAUUCA

AUCAUCCUG






S258-
GAUGAUUUUUAAAAAAU
258
UUGAAUCUAUUUUUUAAA
548


AS548
AGAUUCAA

AAUCAUCCU






S259-
AUGAUUUUUAAAAAAUA
259
UUUGAAUCUAUUUUUUAA
549


AS549
GAUUCAAA

AAAUCAUCC






S260-
UGAUUUUUAAAAAAUAG
260
AUUUGAAUCUAUUUUUUA
550


AS550
AUUCAAAT

AAAAUCAUC






S261-
GAUUUUUAAAAAAUAGA
261
CAUUUGAAUCUAUUUUUU
551


AS551
UUCAAATG

AAAAAUCAU






S262-
AUUUUUAAAAAAUAGAU
262
ACAUUUGAAUCUAUUUUU
552


AS552
UCAAAUGT

UAAAAAUCA






S263-
UUUUUAAAAAAUAGAUU
263
CACAUUUGAAUCUAUUUU
553


AS553
CAAAUGTG

UUAAAAAUC






S264-
AAACGCUUCCUAUAACUC
264
UAAACUCGAGUUAUAGGA
554


AS554
GAGUUTA

AGCGUUUCA






S265-
UAUAGGGGAAGAAAAAG
265
AACAAUAGCUUUUUCUUC
555


AS555
CUAUUGTT

CCCUAUAAA






S266-
AUAGGGGAAGAAAAAGC
266
AAACAAUAGCUUUUUCUU
556


AS556
UAUUGUTT

CCCCUAUAA






S267-
GGGGAAGAAAAAGCUAU
267
UGUAAACAAUAGCUUUUU
557


AS557
UGUUUACA

CUUCCCCUA






S268-
GGGAAGAAAAAGCUAUU
268
UUGUAAACAAUAGCUUUU
558


AS558
GUUUACAA

UCUUCCCCU






S269-
GGAAGAAAAAGCUAUUG
269
AUUGUAAACAAUAGCUUU
559


AS559
UUUACAAT

UUCUUCCCC






S270-
GAAGAAAAAGCUAUUGU
270
AAUUGUAAACAAUAGCUU
560


AS560
UUACAATT

UUUCUUCCC






S271-
AAGAAAAAGCUAUUGUU
271
UAAUUGUAAACAAUAGCU
561


AS561
UACAAUTA

UUUUCUUCC






S272-
AGAAAAAGCUAUUGUUU
272
AUAAUUGUAAACAAUAGC
562


AS562
ACAAUUAT

UUUUUCUUC






S273-
GAAAAAGCUAUUGUUUAC
273
UAUAAUUGUAAACAAUAG
563


AS563
AAUUATA

CUUUUUCUU






S274-
AAAAAGCUAUUGUUUACA
274
AUAUAAUUGUAAACAAUA
564


AS564
AUUAUAT

GCUUUUUCU






S275-
AAAAGCUAUUGUUUACAA
275
GAUAUAAUUGUAAACAAU
565


AS565
UUAUATC

AGCUUUUUC






S276-
AAAGCUAUUGUUUACAAU
276
UGAUAUAAUUGUAAACAA
566


AS566
UAUAUCA

UAGCUUUUU






S277-
AAGCUAUUGUUUACAAUU
277
GUGAUAUAAUUGUAAACA
567


AS567
AUAUCAC

AUAGCUUUU






S278-
AGCUAUUGUUUACAAUUA
278
GGUGAUAUAAUUGUAAAC
568


AS568
UAUCACC

AAUAGCUUU






S279-
GCUAUUGUUUACAAUUAU
279
UGGUGAUAUAAUUGUAAA
569


AS569
AUCACCA

CAAUAGCUU






S280-
CUAUUGUUUACAAUUAUA
280
AUGGUGAUAUAAUUGUAA
570


AS570-
UCACCAT

ACAAUAGCU



M1









S281-
UAUUGUUUACAAUUAUA
281
AAUGGUGAUAUAAUUGUA
571


AS571
UCACCATT

AACAAUAGC






S282-
AUUGUUUACAAUUAUAUC
282
UAAUGGUGAUAUAAUUGU
572


AS572
ACCAUTA

AAACAAUAG






S283-
UUGUUUACAAUUAUAUCA
283
UUAAUGGUGAUAUAAUUG
573


AS573
CCAUUAA

UAAACAAUA






S284-
UGUUUACAAUUAUAUCAC
284
CUUAAUGGUGAUAUAAUU
574


AS574
CAUUAAG

GUAAACAAU






S285-
GUUUACAAUUAUAUCACC
285
CCUUAAUGGUGAUAUAAU
575


AS575
AUUAAGG

UGUAAACAA






S286-
UACAAUUAUAUCACCAUU
286
UUGCCUUAAUGGUGAUAU
576


AS576
AAGGCAA

AAUUGUAAA






S287-
AUUAUAUCACCAUUAAGG
287
GCAGUUGCCUUAAUGGUG
577


AS577
CAACUGC

AUAUAAUUG






S288-
ACUGCUACACCCUGCUUU
288
AGAAUACAAAGCAGGGUG
578


AS578
GUAUUCT

UAGCAGUUG






S289-
CUGCUACACCCUGCUUUG
289
CAGAAUACAAAGCAGGGU
579


AS579
UAUUCTG

GUAGCAGUU






S290-
UGCUACACCCUGCUUUGU
290
CCAGAAUACAAAGCAGGG
580


AS580
AUUCUGG

UGUAGCAGU






S581-
UUCAUAAACAAUGAAUGG
581
UGCCAUUCAUUGUUUAUG
591


AS591
CAGCAGCCGAAAGGCUGC

AAGG






S582-
UCAUAAACAAUGAAUGGC
582
UUGCCAUUCAUUGUUUAU
592


AS592
AAGCAGCCGAAAGGCUGC

GAGG






S583-
GAAACGUGGUUGUGAUGA
583
CUUCAUCACAACCACGUU
593


AS593
AGGCAGCCGAAAGGCUGC

UCGG






S584-
GUUGUGAUGAAGGUAGCU
584
UCAGCUACCUUCAUCACA
594


AS594
GAGCAGCCGAAAGGCUGC

ACGG






S585-
GGUGGAUGAAACUCAGUU
585
UAAACUGAGUUUCAUCCA
595


AS595
UAGCAGCCGAAAGGCUGC

CCGG






S586-
CAGUUUAAGAAGAUCCUC
586
CCGAGGAUCUUCUUAAAC
596


AS596
GGGCAGCCGAAAGGCUGC

UGGG






S587-
UUUAAGAAGAUCCUCGGC
587
UAGCCGAGGAUCUUCUUA
597


AS597
UAGCAGCCGAAAGGCUGC

AAGG






S588-
GUUCUAGAAUUUGAAUUG
588
AUCAAUUCAAAUUCUAGA
598


AS598
AUGCAGCCGAAAGGCUGC

ACGG






S589-
CCUUUUAAACGACAACAA
589
UAUUGUUGUCGUUUAAAA
599


AS599
UAGCAGCCGAAAGGCUGC

GGGG






S590-
AUGAUUUUUAAAAAAUAG
590
AUCUAUUUUUUAAAAAUC
600


AS600
AUGCAGCCGAAAGGCUGC

AUGG






S608-
GAAACUCAGUUUAGCAGC
608
UAAACUGAGUUUCAUCCA
595


AS595
CGAAAGGCUGC

CCGG






S609-
GGUGGAUGAAACUCAGUU
609
UAAACUGAGUUUCAUCCA
595


AS595
UA

CCGG








Claims
  • 1. An oligonucleotide comprising an antisense strand and a sense strand, wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to ALDH2,wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L is a tetraloop and comprises a sequence set forth as GAAA, wherein the GAAA sequence comprises a structure selected from the group consisting of:(i) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-O-methyl modification;(ii) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-OH;(iii) each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification;(iv) each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification;(v) each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification; and(vi) each of the A in the GAAA sequence comprises a 2′-adem modification and the G in the GAAA sequence comprises a 2′-O-methyl modification,and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.
  • 2. The oligonucleotide of claim 1, wherein the antisense strand comprises a sequence set forth in any one of SEQ ID NOs: 591-600.
  • 3. The oligonucleotide of claim 1 or 2, wherein the sense strand comprises a sequence set forth in any one of SEQ ID NOs: 581-590.
  • 4. A pharmaceutical composition comprising an oligonucleotide of any one of claims 1 to 3, and a pharmaceutically acceptable carrier.
  • 5. A method of reducing expression of ALDH2 in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length, wherein the antisense strand has a region of complementarity to a target sequence of ALDH2 as set forth in any one of SEQ ID NOs: 601-607, wherein the region of complementarity is at least 12 contiguous nucleotides in length.
  • 6. The method of claim 5, wherein the region of complementarity is fully complementary to the target sequence of ALDH2.
  • 7. The method of claim 5 or 6, wherein the antisense strand is 19 to 27 nucleotides in length.
  • 8. The method of any one of claims 5 to 7, wherein the region of complementarity to ALDH2 is at least 13 contiguous nucleotides in length
  • 9. The method of any one of claims 5 to 8, wherein the antisense strand comprises a sequence as set forth in any one of SEQ ID NOs: 591-600.
  • 10. The method of any one of claims 5 to 8, wherein the antisense strand consists of a sequence as set forth in any one of SEQ ID NOs: 591-600.
  • 11. The method of any one of claims 5 to 10, wherein the oligonucleotide comprises at least one modified nucleotide.
  • 12. The method of claim 11, wherein the modified nucleotide comprises a 2′-modification.
  • 13. The method of claim 12, wherein the 2′-modification is a modification selected from: 2′-aminoethyl, 2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl, 2′-adem, 2′-aminodiethoxymethanol, and 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid.
  • 14. The method of any one of claims 11 to 13, wherein all of the nucleotides of the oligonucleotide are modified.
  • 15. The method of any one of claims 5 to 14, wherein the oligonucleotide comprises at least one modified internucleotide linkage.
  • 16. The method of claim 15, wherein the at least one modified internucleotide linkage is a phosphorothioate linkage.
  • 17. The method of any one of claims 5 to 16, wherein the antisense strand comprises a phosphate analog at the 4′-carbon of the sugar of the 5′-nucleotide.
  • 18. The method of claim 17, wherein the phosphate analog is oxymethylphosphonate, vinylphosphonate, or malonylphosphonate.
  • 19. A method of reducing expression of ALDH2 in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length, and a sense strand of 15 to 40 nucleotides in length, wherein the sense strand forms a duplex region with the antisense strand, and wherein the antisense strand has a region of complementarity to a target sequence of ALDH2 as set forth in any one of SEQ ID NOs: 601-607, wherein the region of complementarity is at least 12 contiguous nucleotides in length.
  • 20. The method of claim 19, wherein the sense strand is 19 to 40 nucleotides in length.
  • 21. The method of claim 19 or 20, wherein the duplex region is at least 12 nucleotides in length.
  • 22. The method of any one of claims 19 to 21, wherein the region of complementarity to ALDH2 is at least 13 contiguous nucleotides in length.
  • 23. The method of claim 19 or 22, wherein the antisense strand is 19 to 27 nucleotides in length.
  • 24. The method of any one of claims 19 to 23, wherein the antisense strand comprises a sequence as set forth in any one of SEQ ID NOs: 591-600.
  • 25. The method of any one of claims 19 to 24, wherein the sense strand comprises a sequence as set forth in any one of SEQ ID NOs: 581-590, 608, and 609.
  • 26. The method of any one of claims 19 to 23, wherein the antisense strand consists of a sequence as set forth in any one of SEQ ID NOs: 591-600.
  • 27. The method of any one of claims 19 to 23 and 26, wherein the sense strand consists of a sequence as set forth in any one of SEQ ID NOs: 581-590, 608, and 609.
  • 28. The method of any one of claims 19 to 27, wherein the sense strand comprises at its 3′-end a stem-loop sequence set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length.
  • 29. The method of claim 28, wherein L is a tetraloop.
  • 30. The method of claim 28 or 29, wherein L is 4 nucleotides in length.
  • 31. The method of any one of claims 28 to 30, wherein L comprises a sequence set forth as GAAA.
  • 32. The method of claim 31, wherein at least one nucleotide in the GAAA sequence is conjugated to a GalNAc moiety.
  • 33. The method of claim 32, wherein each of the A in GAAA sequence is conjugated to a GalNAc moiety.
  • 34. The method of any one of claims 19 to 33, wherein the antisense strand and the sense strand are not covalently linked.
  • 35. The method of any one of claims 19 to 34, wherein the oligonucleotide comprises at least one modified nucleotide.
  • 36. The method of claim 35, wherein the modified nucleotide comprises a 2′-modification.
  • 37. The method of claim 36, wherein the 2′-modification is a modification selected from: 2′-aminoethyl, 2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl, 2′-adem, 2′-aminodiethoxymethanol, and 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid.
  • 38. The method of any one of claims 35 to 37, wherein all of the nucleotides of the oligonucleotide are modified.
  • 39. The method of any one of claims 19 to 38, wherein the oligonucleotide comprises at least one modified internucleotide linkage.
  • 40. The method of claim 39, wherein the at least one modified internucleotide linkage is a phosphorothioate linkage.
  • 41. The method of any one of claims 19 to 40, wherein the antisense strand comprises a phosphate analog at the 4′-carbon of the sugar of the 5′-nucleotide.
  • 42. The method of claim 41, wherein the phosphate analog is oxymethylphosphonate, vinylphosphonate, or malonylphosphonate.
  • 43. The method of any one of claims 35 to 42, wherein the G in the GAAA sequence of claim 31 comprises a 2′-O-methyl modification.
  • 44. The method of any one of claims 35 to 42, wherein the G in the GAAA sequence of claim 31 comprises a 2′-OH.
  • 45. The method of any one of claims 35 to 42, wherein each of the nucleotides in the GAAA sequence of claim 31 comprises a 2′-O-methyl modification.
  • 46. The method of any one of claims 35 to 42, wherein for the GAAA sequence of claim 31, each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification.
  • 47. The method of any one of claims 35 to 42, wherein for the GAAA sequence of claim 31, each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification.
  • 48. The method of any one of claims 35 to 42, wherein for the GAAA sequence of claim 31, each of the A in the GAAA sequence comprises a 2′-adem modification and the G in the GAAA sequence comprises a 2′-O-methyl modification.
  • 49. The method of any one of claims 5 to 48, wherein the oligonucleotide is administered intrathecally, intraventricularly, intracavitary, or interstitially.
  • 50. The method of any one of claims 5 to 49, wherein the oligonucleotide is administered via injection or infusion.
  • 51. The method of any one of claims 5 to 50, wherein the subject has a neurological disorder.
  • 52. The method of claim 51, wherein the neurological disorder is selected from: neurodegenerative diseases, cognitive disorders, and anxiety disorders.
  • 53. A method of reducing expression of ALDH2 in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand and a sense strand, wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to ALDH2,wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length,and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.
  • 54. A method of reducing expression of ALDH2 in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand and a sense strand that are not covalently linked, wherein the antisense strand comprises a sequence as set forth in SEQ ID NO: 595 and the sense strand comprises a sequence as set forth in SEQ ID NO: 585,wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L is a tetraloop comprising a sequence set forth as GAAA, and wherein the GAAA sequence comprises a structure selected from the group consisting of:(i) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-O-methyl modification;(ii) each of the A in GAAA sequence is conjugated to a GalNAc moiety, and the G in the GAAA sequence comprises a 2′-OH;(iii) each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification;(iv) each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification;(v) each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification; and(vi) each of the A in the GAAA sequence comprises a 2′-adem modification and the G in the GAAA sequence comprises a 2′-O-methyl modification.
  • 55. A method of reducing expression of ALDH2 in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand and a sense strand that are not covalently linked, wherein the antisense strand comprises a sequence as set forth in SEQ ID NO: 595 and the sense strand comprises a sequence as set forth in SEQ ID NO: 609.
  • 56. The method of any one of claims 5 to 55, wherein the oligonucleotide reduces expression of ALDH2 that is detectable in somatosensory cortex, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, and/or spinal cord.
  • 57. A method of treating a neurological disorder associated with ALDH2 expression, the method comprising administering to the cerebrospinal fluid of a subject in need thereof an oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length, wherein the antisense strand has a region of complementarity to a target sequence of ALDH2 as set forth in any one of SEQ ID NOs: 601-607, wherein the region of complementarity is at least 12 contiguous nucleotides in length.
  • 58. A method treating a neurological disorder associated with ALDH2 expression, the method comprising administering to the cerebrospinal fluid of a subject in need thereof an oligonucleotide comprising an antisense strand and a sense strand, wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to ALDH2,wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length,and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.
  • 59. The method of claim 57 or 58, wherein the neurological disorder is a neurodegenerative disease.
  • 60. The method of claim 59, wherein the neurological disorder is an anxiety disorder.
  • 61. The method of any one of claims 57 to 60, wherein the oligonucleotide is administered intrathecally, intraventricularly, intracavitary, or interstitially.
  • 62. The method of any one of claims 57 to 61, wherein the oligonucleotide is administered via injection or infusion.
  • 63. The method of any one of claims 57 to 62, wherein the oligonucleotide reduces expression of ALDH2 that is detectable in somatosensory cortex, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, and/or spinal cord.
  • 64. A method of reducing expression of a target gene in a subject, the method comprising administering an oligonucleotide to the cerebrospinal fluid of the subject, wherein the oligonucleotide comprises an antisense strand and a sense strand, wherein the antisense strand is 21 to 27 nucleotides in length and has a region of complementarity to the target gene,wherein the sense strand comprises at its 3′-end a stem-loop set forth as: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3 to 5 nucleotides in length,and wherein the antisense strand and the sense strand form a duplex structure of at least 12 nucleotides in length but are not covalently linked.
  • 65. The method of claim 64, wherein L is a tetraloop.
  • 66. The method of claim 65, wherein L is 4 nucleotides in length.
  • 67. The method of any one of claims 64 to 66, wherein L comprises a sequence set forth as GAAA.
  • 68. The method of claim 67, wherein the GAAA sequence comprises a structure selected from the following: (i) each of the A in GAAA sequence is conjugated to a GalNAc moiety;(ii) the G in the GAAA sequence comprises a 2′-O-methyl modification;(iii) the G in the GAAA sequence comprises a 2′-OH;(iv) each of the nucleotide in the GAAA sequence comprises a 2′-O-methyl modification;(v) each of the A in the GAAA sequence comprises a 2′-OH and the G in the GAAA sequence comprises a 2′-O-methyl modification;(vi) each of the A in the GAAA sequence comprises a 2′-O-methoxyethyl modification and the G in the GAAA sequence comprises a 2′-O-methyl modification; and(vii) each of the A in the GAAA sequence comprises a 2′-adem and the G in the GAAA sequence comprises a 2′-O-methyl modification.
  • 69. A method of reducing expression of a target gene of interest in a subject, the method comprising administering to the cerebrospinal fluid of the subject an oligonucleotide comprising an antisense strand of 15 to 30 nucleotides in length, wherein the antisense strand has a region of complementarity to a target sequence of the gene of interest that is expressed in the CNS, wherein the region of complementarity is at least 12 contiguous nucleotides in length.
  • 70. The method of any one of claims 64 to 69, wherein the target gene is selected from the group consisting of ALDH2, Ataxin-1, Ataxin-3, APP, BACE1, DYT1, and SOD1.
  • 71. The method of claim 64 to 70, wherein the oligonucleotide reduces expression of the target gene in somatosensory cortex, hippocampus, frontal cortex, striatum, hypothalamus, cerebellum, and/or spinal cord.
  • 72. The method of any one of claims 64 to 71, wherein the oligonucleotide further comprises elements that are degraded by nucleases outside the CNS such that said nucleotide is no longer capable of reducing expression of a gene of interest in a subject in tissues outside the CNS.
  • 73. The method of claim 72, wherein the oligonucleotide further comprises modifications such that it cannot easily exit the CNS.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/829,595, filed Apr. 4, 2019, the entire contents of which are incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2020/026717 4/3/2020 WO 00
Provisional Applications (1)
Number Date Country
62829595 Apr 2019 US